Formulation Development and Evaluation of Regio-Selective Bilayer Floating Tablet of Propranolol Hydrochloride for Sustained Release and Rosuvastatin Calcium for Immediate Release by Kishore, Kumar
FORMULATION DEVELOPMENT AND EVALUATION OF 
BILAYER REGIO-SELECTIVE FLOATING TABLETS OF 
PROPRANOLOL HYDROCHLORIDE AND ROSUVASTATIN 
CALCIUM 
 
 A Dissertation submitted to 
        THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY                                     
         CHENNAI-32. 
 
 
 
 
 
 
In partial fulfillment of the requirements for the award of degree of 
MASTER OF PHARMACY 
IN  
PHARMACEUTICS 
 
Submitted by 
Register no: 261211255 
  
Under the guidance of 
Prof.K.Elango, M.Pharm. (Ph.D.) 
Professor & Head  
Department of Pharmaceutics 
 
 
 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI-600 003 
APRIL-2014 
FORMULATION DEVELOPMENT AND EVALUATION OF 
REGIO- SELECTIVE BILAYER FLOATING TABLETS OF 
PROPRANOLOL HYDROCHLORIDE FOR SUSTAINED 
RELEASE AND ROSUVASTATIN CALCIUM FOR IMMEDIATE 
RELEASE 
 
 A Dissertation submitted to 
        THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY                                      
CHENNAI-32. 
 
 
 
In partial fulfillment of the requirements for the award of degree of 
MASTER OF PHARMACY 
IN 
PHARMACEUTICS 
 
Submitted by 
Register no: 261211255 
 
Under the guidance of 
Prof.K.Elango, M.Pharm., (Ph.D.) 
Professor & Head  
Department of Pharmaceutics 
 
 
 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI-600 003. 
APRIL-2014 
 
 
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI-600 003 
TAMILNADU 
 
 
                    
DATE: 
 
 
 
 
 
 
                          This is to certify that the dissertation entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF REGIO- SELECTIVE BILAYER 
FLOATING TABLET OF PROPRANOLOL HYDROCHLORIDE FOR SUSTAINED 
RELEASE AND ROSUVASTATIN CALCIUM FOR IMMEDIATE RELEASE” submitted 
by the candidate with Register No. 261211255 for The Tamil Nadu Dr. M.G.R. Medical 
University examinations is evaluated. 
 
 
 
 
                                                                                           
                                     
Evaluated  
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI-600 003 
TAMILNADU 
 
 
                    
 
 
 
 
CERTIFICATE 
 
  This is to certify that the dissertation entitled “FORMULATION DEVELOPMENT 
AND EVALUATION OF REGIO-SELECTIVE BILAYER FLOATING TABLETS OF 
PROPRANOLOL FOR SUSTAINED RELEASE AND ROSUVASTATIN CALCIUM 
FOR IMMEDIATE RELEASE” submitted by the candidate with Reg. No.261211255 in 
partial fulfillment of the requirements for the award of the degree of Master of Pharmacy in 
Pharmaceutics by The Tamil Nadu Dr.M.G.R.Medical University is a Bonafide work done by 
them during the academic year 2013-2014. 
 
Place: Chennai -03.         
Date:  
Dr.A.Jerad Suresh  
 
 
 
 
 
 
 
 
  
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI-600 003 
TAMILNADU 
 
 
                 
 
 
 
 
 
CERTIFICATE 
 
  This is to certify that the dissertation entitled “FORMULATION DEVELOPMENT 
AND EVALUATION OF REGIO-SELECTIVE BILAYER FLOATING TABLETS OF 
PROPRANOLOL FOR SUSTAINED RELEASE AND ROSUVASTATIN CALCIUM 
FOR IMMEDIATE RELEASE” submitted by the candidate with Reg. No.261211255 in 
partial fulfillment of the requirements for the award of the degree of MASTER OF 
PHARMACY in PHARMACEUTICS by The Tamil Nadu Dr.M.G.R.Medical University is a 
bonafide work done by him during the academic year 2013-2014 under my guidance.  
 
Place: Chennai -03.         
Date:  
Prof. K.Elango  
 
 
 
 
 
 
 
 
 
 ACKNOWLEDGEMENT 
Though words are seldom sufficient to express gratitude and feelings, it somehow gives 
us an opportunity to acknowledge those who helped us during the tenure of our study. The work 
of dissertation preparation was a challenging task and fascinating experience. 
 
First of all we thank the Almighty for giving us strength, endurance and showering his 
blessing to undertake this project and pursue with full dedication and giving us courage always 
to do hard work and present the work for which I am extremely indebted. 
 
We acknowledge our sincere thanks to prof. Dr. A. Jerad Suresh M.pharm.,Ph.D. 
.,MBA, Principal, college of pharmacy ,Madras Medical College, Chennai, for his continuous 
support in carrying out our project work in this institution. 
 
We consider ourselves very much lucky with profound privilege and great pleasure in 
expressing our deep sense of gratitude to work under the guidance of Prof. 
Mr.K.Elango,M.pharm., (Ph.D.), Head, Department of pharmaceutics, College of Pharmacy, 
Madras Medical College, Chennai for his continuous guidance, supportive suggestion, 
innovative ideas, with constant inspiration, help and encouragement have always propelled us to 
perform better. 
 
I express my heartfelt thanks to Mr. Dilip kumar, Assistant drugs controller, DMS 
campus for providing drug for my research work. 
 
We express my deepest and very special and thanks to Sai supreme Chemicals for 
providing drug for my research work.  
 
It’s a great pleasure for us to acknowledge our sincere thanks to all my teaching staff 
members  Dr.N.Deattu,M.Pharm., Ph.D., Mrs.S.Daisychellakumari,M.pharm.,  Mrs.R.Devi 
Damayanthi, M.Pharm., of the Department of Pharmaceutics, College of Pharmacy, Madras 
Medical College,Chennai-03. 
 We extend our thanks to all non-teaching staff members Mr.E.Arivazhagan, 
Mr.R.Marthandam, Mrs. R .Shankari Department of Pharmaceutics, College of Pharmacy, 
Madras Medical College, Chennai-03. 
 
          We would like to thank our seniors and friends A.Balaguru, K.Sathiyaraj 
Al.Akilandeshwari, U.Catherin, S.Chinnaraja, D.David Selvakumar, B.Priya, R.Rajakumari, 
P.Ramu, and G.Suhasini who stood beside us throughout our project. 
 
We extend my cordial thanks to our seniors and to our juniors for their kind support and 
co-operation. 
 
Most of all we would like to thank our beloved parents for their priceless support, love 
and encouragement throughout the entire tenure of this course. 
 
 
ABBREVIATIONS 
GRDDS  - Gastro retentive drug delivery system 
GIT   - Gastro intestinal tract 
GRT   - Gastric emptying time 
FDDS   - Migrating myoelectric complex 
GFR   - Glomerular filtration rate  
BMI   - Body mass index 
HPMC  - Hydroxy propyl methyl cellulose 
PVP   - Poly vinyl pyrrolidone 
SSG   - Sodium starch glycolate 
MMC   - Microcrystalline cellulose 
IPA   - Isopropyl alcohol 
PH   - Propranolol hydrochloride 
RC   - Rosuvastatin calcium 
RBFT   - Regio-selective bilayer floating tablet 
SD   - Solid dispersion  
IR-SD   - Immediate release solid dispersion compressed tablets  
EC   - Ethyl cellulose 
Mg   - Milligram  
ml   - Milliliter 
µg   - Microgram 
%   - Percentage 
RPM   - Revolution per minute 
FTIR   - Fourier transform infra-red 
RH   - Relative humidity  
 
 
 INDEX 
S.NO TITLE PAGE NO 
1 INTRODUCTION  1 
2 LITRATURE REVIEW 23 
3 AIM AND PLAN OF WORK 36 
4 RATIONALE OF PROJECT WORK 39 
5 DISEASE PROFILE  42 
6 DRUG PROFILE 52 
7 EXCIPIENT PROFILE 58 
8 MATERIALS AND METHODS 74 
9 RESULTS AND DISCUSSION 
 
92 
10 SUMMARY AND CONLUTION  132 
11 BIBLIOGRAPHY 135 
 
  
 
  
 
 
 
INTRODUCTION 
 
Introduction 
 
Department of pharmaceutics, Madras Medical College. Page 1 
 
INTRODUCTION
1
 
           Oral route is the most widely used route of administration among all the routes 
that have been developed for systemic controlled delivery of drugs. 
This is due to following reasons: 
1. Oral route is most convenient and uncomplicated  
2. Ease of administration and safe 
3. Improved patient compliance  
4. Cost-effective  
 
           Oral solid dosage forms such as tablets and capsules have been formulated and 
developed nowadays since they are the most effective routes of administration of a new 
drug. Pharmaceutical products designed for oral delivery and currently available on the 
prescription and over the counter markets are mostly immediate release types, which are 
designed for immediate release of drug for rapid absorption. Many new generations of 
pharmaceutical products called controlled and sustained release drug delivery systems 
have also been developed. So the combination of both will be very much useful for 
immediate response and for maintaining the duration of action. 
 
TABLETS  
        Tablet is defined as a compressed solid dosage form containing medicaments with or 
without excipients. As per Indian pharmacopoeia, pharmaceutical tablets are solid, flat or 
biconvex, unit dosage form, prepared by compressing a drug or mixture of drugs, with or 
without diluents. They vary in shape and differ greatly in size and weight, depending on 
the amount of medicinal substances and the intended mode of administration. It is the 
most popular dosage form and 70% of the total medicines are dispensed in the form of 
tablet. Tablets are solid preparations each containing single dose of one or more active 
medicaments and usually obtained by compressing uniform volumes of particles. Tablets 
are intended for oral administration. Some are swallowed whole or after being chewed, 
some are dissolved or dispersed in water before being administered and some are retained 
in the mouth where the active medicament is liberated. They may have lines or break-
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marks and may bear a symbol or other markings. Tablets may be coated or uncoated. 
They are sufficiently hard to withstand handling without crumbling or breaking   
 
 
 
Fig 1: Plasma concentration – Time profile of conventional multiple dosing, single 
dose of sustained release and controlled release formulation  
 
There are some limitations of conventional tablets. They are  
 Drugs having  short half-life require frequent administration 
 The typical peak valley plasma concentration time profile of immediate release 
makes the attainment of steady state concentration difficult 
 The fluctuations of drug concentration in plasma can lead to under medication or 
over medication  
 The fluctuating drug concentration in plasma can lead to precipitation of adverse 
effects especially for a drug with small therapeutic index  
CONTROLLED RELEASE DRUG DELIVERY SYSTEMS
2
 
Controlled release drug delivery system was designed to deliver the for a prolonged 
period. Safe and effective blood levels are maintained for longer period as the system 
continues to deliver the drug. Controlled drug delivery usually results in constant blood 
levels of the drug as compared to the uncontrolled fluctuations observed when multiple 
doses of quick releasing conventional dosage forms are administered to a patient
2
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Advantages of controlled drug delivery systems 
 Avoid patient compliance problems. 
 Less total drug is used. 
 Minimize local side effects and systemic side effects.  
 Obtain less reduction in drug activity in chronic use. 
 Minimize the drug accumulation with chronic dosing. 
 Improve efficiency in treatment and cures the condition more promptly. 
 Bioavailability of some drugs is improved. 
 Make use of special effects, e.g., sustained release aspirin for morning relief of 
arthritis by dosing before bed. 
Disadvantages 
 Decreased systemic availability in comparison to immediate release formulation 
or conventional dosage forms, which may be due to incomplete release, increased 
first pass metabolism, increased instability, insufficient residence time for 
complete release, site specific absorption,pH dependent stability etc. 
 Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions. 
 Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths. 
 Stability problems 
GASTRORETENTIVE DRUG DELIVERY SYSTEMS
3
:  
Oral controlled release dosage forms are developed due to their therapeutic 
advantages such as patient compliance, ease of administration and flexibility in 
formulation. However this approach has several physiological difficulties such as 
inability to locate the dosage form at the desired region of the gastrointestinal tract (GIT) 
due to variable gastric emptying time. The gastric emptying time in human normally 
ranges from 2-3 hrs through which the major absorption zone (stomach and upper part of 
intestine) passes through.so the dosage form can result in incomplete drug absorption 
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from the delivery system and leading to reduced efficacy of the administered dose. 
Therefore, the control of placement of a drug delivery system in a specific region of the 
GIT offers greater advantage. The drugs characterized by a narrow absorption window in 
the GIT or drugs with a stability problem in the intestine can be benefitted by this 
approach. These have led to the development of a unique oral controlled release dosage 
form with gastro retentive properties. After oral administration, such a dosage form 
would be retained in the stomach and release the drug there in a controlled and prolonged 
manner, so that the drug could be supplied continuously to its absorption sites in the 
upper GIT.     
ANATOMICAL AND MECHANICAL ASPECTS OF THE STOMACH
4
: 
A basic understanding of the anatomical and mechanical aspects of the stomach is 
needed for a pharmaceutical formulator to develop successful gastro retentive 
formulation .the stomach is divided into 4 regions – the cardia, fundus, body and pylorus. 
Gastric emptying occurs both during fasted and fed states. The pattern differs in two 
states. In the fasted state, the pattern is characterized by a series of motor activities 
known as inter- digestive myoelectric cycle or Migrating Motor Complex (MMC) which 
usually occurs every 80-120mins. 
 
Fig 2: Anatomical representation of the stomach 
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Gastric emptying is divided into 4 phases are as following: 
This is called the inter-digestive myloelectric cycle or migrating myloelectric cycle 
(MMC) which is further divided into following 4 phases as described by Wilson and 
Washington. 
 
MMC phases 
 
Phase Time Type 
   
I (basal phase) Lasts  from  40  to  60 With rare contractions. 
  Minutes  
   
II (pre-burst phase) lasts for 40 to 60 minutes 
with  intermittent  action  
potential 
   And contractions. 
    
III (burst phase) lasts for 4 to 6 minutes 
intense and regular contractions 
for 
   Short period. 
    
IV (digestive lasts for 0 to 5 minutes continuous contractions 
motility pattern)   
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Fig 3: Motility patterns of the GIT in the fasted state 
 
 
 
 
 
 
 
 
Influencing factors over gastric retention physicochemical factors:  
 Density  
 Size 
 Shape of dosage form 
 Food and drug interactions  e.g., Anticholinergic agents  (e.g., atropine, 
propantheline) opiates(e.g., codeine)  
 Prokinetic agents (e.g. Metoclopramide, cisapride) 
Biological factors: 
 Gender 
 Posture 
 Age 
 Body mass index 
 Disease states(e.g., diabetes, crohn’s disease) 
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Details are as follows: 
 Density  
o The density of a dosage form also affects the gastric emptying rate and 
determines the location of the system in the stomach. Dosage forms 
having a density lower than the gastric contents can float to the surface, 
while high density systems sink to bottom of the stomach. Both positions 
may isolate the dosage system from the pylorus. A density of < 1.0 gm / 
cm3 is required to exhibit floating property. 
 
 Food 
o Food affects the GRT of dosage forms depending on its nature, caloric 
content, and the frequency of intake. 
 Nature of meal-feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of stomach to a fed-state, thus decreasing the gastric emptying 
rate and prolonging drug release. 
 
 Caloric content-GRT can be increased by 4-10 hours with a meal that is high in 
proteins and fats. 
 Frequency of feed- The GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of 
myoelectric motor complex.  
 Size  
o Small-size tablets are emptied from the stomach during the digestive 
phase, while larger units are expelled during housekeeper waves. Floating 
units with a diameter equal to or less than 7.5mm had longer GRTs 
compared to non-floating units. GRT were similar for floating and non-
floating units having a larger diameter of 9.9mm. 
 Shape 
o Ring-shaped and tetrahedron-shaped devices have a better gastric 
residence time as compared with other shapes. 
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 Gender 
o Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with 
their age and race matched female counterparts (4.6±1.2 hours), regardless 
of the weight, height and body surface)  
 
 Posture 
o The mean GRT for volunteers in the supine state was not significant from 
that in the upright, ambulatory state.  
 
 Fed or unfed state – under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) 
that occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the 
stomach and, if the timing of administration of the formulation coincides with that 
of the MMC, the GRT of the unit can be expected to be very short. However, in 
the fed state, MMC is delayed and GRT is considerably longer. 
 
 Age – elderly people, especially those over 70, have a significantly longer GRT. 
 
 
Fig 4: Mechanism of gastro-retention of the drug 
 
 
 
Introduction 
 
Department of pharmaceutics, Madras Medical College. Page 9 
 
 
GASTRORETENTIVE DRUG DELIVERY SYSTEMS
5
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REGIO-SELECTIVE FLOATING DRUG DELIVERY SYSTEMS
 
Floating drug delivery system or hydro dynamically balanced systems have a bulk 
density lower than gastric contents and thus remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolonged period of time. While the system is 
floating on the gastric contents, the drug is released slowly at a desired rate from the 
system. After the release of the drug, the residual system is emptied from the stomach. 
This results in an increase in the GRT and a better control of fluctuations in plasma drug 
concentrations.  
However, besides a minimal gastric content needed to allow the proper 
achievement of the buoyancy retention principle, a minimal level of floating force (F) is 
also required to keep the dosage form reliably buoyant on the surface of the meal. 
 To measure the floating force kinetics, a novel apparatus used for determination 
of resultant weight (RW). The RW apparatus operates by measuring continuously the 
force equivalent to F (as a function of time) that is required to maintain the submerged 
object. The object floats better if RW is on the higher positive side.  
 
Advantages of Floating drug delivery system
6 
A floating drug delivery system offers numerous advantages over conventional 
drug delivery System: 
Sustained drug delivery A floating drug delivery system can remain in the stomach for 
several hours and the assumed prolongation in the gastric retention is postulated to cause 
sustained drug release behavior. 
 
Site-specific drug delivery Targeting of drug to stomach appears to be useful for all 
substances intended to produce a lasting local action on the gastro duodenal wall.  
 
Pharmacokinetic advantage In addition, with the total gastrointestinal transit duration is 
increased, a greater amount of drug may be delivered and thus the relative bioavailability 
will consequently be increased  
 
Targeted therapy for local ailments in the upper GIT The prolonged and sustained 
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administration of the drug from GRDF to the stomach may be advantageous for local 
therapy in the stomach and small intestine. Eg. Antibiotic for Helicobacter pylori based 
ulcer, Antacid.  
 
Reduced counter-activity of the body Slow input of the drug into the body was shown 
to minimize the counter activity leading to higher drug efficiency. 
 
Minimized adverse activity at the colon Retention of the drug in the GRDF at the 
stomach minimizes the amount of drug that reaches the colon. Thus, undesirable 
activities of the drug in colon may be prevented.  
 
Enhanced bioavailability The bioavailability of riboflavin CR-GRDF is significantly 
enhanced in comparison to the administration of non-GRDF CR polymeric formulations. 
 
Disadvantages of floating drug delivery system 
 
Floating system is not feasible for those drugs that have solubility or stability 
problem in G.I.Tract.  
These systems require a high level of fluid in the stomach for drug delivery to 
float and work efficiently-coat, water. The drugs that are significantly absorbed 
throughout gastrointestinal tract, which undergo significant first pass metabolism, are 
only desirable candidate. 
 
Three major requirements of FDDS are  
 It must form a cohesive gel barrier.  
 It must maintain specific gravity lower than gastric contents (1.004-1.01g//c). 
 It should release contents slowly to serve as a reservoir.  
 
Criteria for selection of drug candidate for FDDS  
 
Desirable half-life If the drug has a short half-life of less than 2 hours, the dosage form 
may contain a prohibitively large quantity of the drug.  
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High therapeutic index Drugs with low therapeutic index are not suitable for 
incorporation in controlled release formulations. e.g. Digitoxin.  
 
Small dose the dose of a drug in the conventional dosage form is high, its suitability as a 
candidate for controlled release is seriously undermined  
 
Aqueous solubility Drugs with aqueous solubility make good candidates for controlled 
release dosage form.  
Stability to wide pH range, GI enzymes and flora Stability of the drug in the GI 
contents is important to ensure a complete and reproducible drug input into the body. 
Typically the drug must be stable in the pH range of 1 to 8.  
First pass clearance Delivery of the drug to the body in desired concentration is 
seriously hampered in case of drugs undergoing extensive hepatic first pass metabolism, 
when administered in controlled release form. Saturable hepatic metabolism may render a 
drug unsuitable because systemic availability for such drug is highly reduced when the 
input rate is small.  
Drugs those are Unsuitable for Gastro retentive Drug Delivery Systems  
 
 Drugs that have very limited acid solubility e.g. phenytoin etc.  
 
 Drugs that suffer instability in the gastric environment e.g. erythromycin etc.  
 
 Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc. 
 
Classification of FDDS
7
 
 
A. Single Unit Floating Dosage Systems 
a) Effervescent Systems (Gas-generating Systems)  
b) Non-effervescent Systems  
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B. Multiple Unit Floating Dosage Systems  
a) Non-effervescent Systems  
b) Effervescent Systems (Gas-generating Systems)  
c) Hollow Microspheres  
d). Raft Forming Systems 
Types of floating drug delivery system 
Based on the mechanism of buoyancy, two distinctly different technologies 
have been utilized in the development of FDDS 
 
(A). Non-Effervescent FDDS 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in 
noneffervescent FDDS are gel forming or highly swellable cellulose type 
hydrocolloids, hydrophilic gums, polysaccharides and matrix forming materials such as 
polycarbonate, polyacrylate, polymethacrylate, polystyrene as well as bioadhesive 
polymers such as Chitosan and carbopol. 
 
 
The various types of this system are as: 
 
(1). Colloidal gel barrier systems 
 
Hydro-dynamically balanced system (HBS) of this type contains drug with gel 
forming or Swellable cellulose type hydrocolloids, polysaccharides and matrix forming 
polymers. They help in prolonging the GI residence time and maximize drug reaching 
its absorption site in the solution form ready for absorption. These systems incorporate 
high levels (20 to 75 % 
w/w) of one or more gel forming highly swellable cellulose type hydrocolloids e.g. 
Hydroxyethyl cellulose, hydroxyropyl cellulose, hydroxyropyl methyl cellulose, 
sodium carboxymethylcellulose incorporated either in tablets or capsules.
[60]
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(a). Single Layer Floating Tablets: They are formulated by intimate mixing of drug 
with a gel-forming hydrocolloid, which swells in contact with gastric fluid and 
maintains bulk density of less than unity. They are formulated by intimate mixing of 
drug with low-density enteric materials such as HPMC. 
 
(b). Bi-layer Floating Tablets: A bi-layer tablet contain two layer one immediate 
release layer which releases initial dose from system while the another sustained release 
layer absorbs gastric fluid, forming an impermeable colloidal gel barrier on its surface, 
and maintain a bulk density of less than unity and thereby it remains buoyant in the 
stomach. 
 
 
Figure 5: Intragastric floating tablet. 
 
 
 
 
 
 
 
 
 
 
(2). Micro porous compartment system 
This technology is comprised of encapsulation of a drug reservoir inside a micro porous 
compartment with pores along its top and bottom surfaces. The peripheral walls of the 
drug reservoir compartment are completely sealed to prevent any direct contact of gastric 
mucosal surface with undissolved drug. In stomach, the floatation chamber containing 
entrapped air causes the delivery system to float over the gastric contents. Gastric fluid 
enters through the pores, dissolves the drug and carries the dissolved drug for continuous 
transport across the Intestine for absorption. 
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Figure 6: Micro porous intra-gastric floating drug delivery device 
 
 
 
 
 
 
 
(3). Alginate Beads 
 
Multi-unit floating dosage forms were developed from freeze dried calcium alginate. 
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping 
sodium alginate solution into aqueous solution of calcium chloride, causing 
precipitation of calcium alginate leading to formation of porous system, which can 
maintain a floating force for over 12 hours. When compared with solid beads, which 
gave a short residence time of 1 hour, and these floating beads gave a prolonged 
residence time of more than 5.5 hours. 
(4). Hollow Microspheres 
 
Hollow microspheres (Microballoons), loaded with drug in their outer polymer shells 
are prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer is poured into an 
agitated aqueous solution of PVA that is thermally controlled at 40 °C. The gas phase 
generated in dispersed polymer droplet by evaporation of dichloromethane forms an 
internal cavity in microsphere of polymer with drug. The Microballoons float 
continuously over the surface of acidic dissolution media containing surfactant for more 
than 12 hours. 
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Fig 7: Mechanism of micro balloon formation by emulsion-solvent diffusion 
Method. 
 
 
 
 
 
 
(B) Effervescent FDDS
8 
 
A drug delivery system can be made to float in the stomach by incorporating a floating 
chamber, which may be filled with vacuum, air or inert gas. The gas in floating 
chamber can be introduced either by volatilization of an organic solvent or by 
effervescent reaction between organic acids and bicarbonate salts. 
Fig 8: Floating pills a) The penetration of water into effervescent layer leads to a 
CO2             generation and makes the system to float. 
 
 
 
 
 
 
 
 
(1) Volatile liquid containing system 
 
The GRT of a drug delivery system can be sustained by incorporating an inflatable 
chamber, which contains a liquid e.g. ether, cyclopentane, that gasifies at body 
temperature to cause the inflatation of the chamber in the stomach. The device may also 
consist of a bioerodible plug made up of Poly vinyl alcohol, Polyethylene, etc. that 
gradually dissolves causing the inflatable chamber to release gas and collapse after a 
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predetermined time to permit the spontaneous ejection of the inflatable systems from 
the stomach
9.
 
 
(a) Inflatable gastrointestinal delivery systems 
In these systems an inflatable chamber is incorporated, which contains liquid that 
gasifies at body temperature to cause the chamber to inflate in the stomach. The 
inflatable chamber automatically inflates and retains the drug reservoir compartment in 
floating position. The drug continuously released from the reservoir into the gastric fluid. 
 
Fig 9: Inflatable gastrointestinal delivery system 
 
 
 
 
 
 
 
 
 
 
 
 
(b) Intragastric osmotically controlled drug delivery system 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a 
liquid that gasifies at body temperature to inflate the bag. The osmotic pressure 
controlled drug delivery device consists of two components; drug reservoir 
compartment and an osmotically active compartment.  
The drug reservoir compartment is enclosed by a pressure responsive collapsible 
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bag, which is impermeable to vapour and liquid and has a drug delivery orifice. The 
osmotically active compartment contains an osmotically active salt and is enclosed 
within a semi permeable housing. In the stomach, the water in the GI fluid is 
continuously absorbed through the semipermeable membrane into osmotically active 
compartment to dissolve the osmotically active salt. An osmotic pressure is thus created 
which acts on the collapsible bag and turns in forces the drug reservoir compartment to 
reduce its volume and activate the drug reservoir compartment to reduce its volume and 
activate the drug release in solution form through the delivery orifice. The floating 
support is also made to contain a bioerodible plug that erodes after a predetermined 
time to deflate the support. The deflated drug delivery system is then emptied from the 
stomach 
 
Fig 10: Intragastric osmotically controlled drug delivery system 
 
 
 
 
 
 
 
 
 (2) Gas-generating Systems: 
 
These buoyant delivery systems utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets 
entrapped in the gellified hydrocolloid layer of the systems thus decreasing its specific 
gravity and making it to float over chime. 
(3). Raft Forming systems 
Here, a gel-forming solution (e.g. Sodium alginate solution containing carbonates 
or bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 
bubbles on contact with gastric fluid. Formulations also typically contain antacids such 
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as aluminum hydroxide or calcium carbonate to reduce gastric acidity.  
Because raft forming systems produce a layer on the top of gastric fluids, they are 
often used for gastro-oesophageal reflux treatment as with Liquid Gaviscon 
(GlaxoSmithKline). 
 
Fig 11: Mechanism of floating drug delivery system 
 
 
 
 
 
 
 
The magnitude and direction of force/resultant weight (up or down) is 
corresponding to its buoyancy force (F buoyancy) and gravity force (Fgravity) acting on 
dosage form  
F = F buoyancy – F gravity 
F = Df g V – Ds g V 
F = (Df – Ds) g V 
F = (Df – M/V) g V 
 
Where,  
            F    = resultant weight of object 
            Df  = Density of Fluid  
            DS = Density of Solid object  
            g    = Gravitational force  
            M  = Mass of dosage form  
            V   = Volume of dosage form 
 
So when Ds, density of dosage form is lower, F force is positive gives buoyancy 
and when it is Ds is higher, F will negative shows sinking.  
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Plot of F vs. Time is drawn and floating time is time when F approaches to zero from 
positive values. 
Fig 12: Effect of buoyancy force and gravity force on drug delivery system 
 
Effervescent (gas generating) systems 
Floatability can be achieved by generation of gas bubbles. These buoyant systems 
utilize matrices prepared with swellable polymers such as polysaccharides (e.g. chitosan), 
effervescent Components (e.g. sodium bicarbonate, citric acid or tartaric acid). The 
optimal stoicheometric ratio of citric acid and sodium bicarbonate for gas generation is 
reported to be 0.76: 1. In this system carbon dioxide is released and causes the 
formulation to float in the stomach.  
 
Other approaches and materials that have been reported are a mixture of sodium 
alginate and sodium bicarbonate, multiple unit floating dosage forms that generate gas 
(carbon dioxide) when ingested, floating mini capsules with a core of sodium 
bicarbonate, lactose and polyvinyl pyrrolidone (PVP) coated with hydroxyl propyl 
methylcellulose (HPMC), and floating system based on ion exchange resin technology.  
 
Bilayer or multilayer system has also been designed. Drugs and excipients can be 
formulated independently and the gas generating material can be incorporated into any of 
the layers. Further modifications involve coating of the matrix with a polymer which is 
permeable to water, but not to carbon dioxide. 
NON-FLOATING SYSTEMS 
These are another class of gastroretentive drug delivery systems which do not float 
but remain in the stomach for a prolonged time period. These systems are formulated by 
any of the following approaches. 
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i. Bioadhesive systems: These types of systems adhere to the biological membrane 
(mucosa) of the stomach and maintain intimate contact with the membrane for a 
longer time and hence retains in stomach for its prolonged release. These systems 
are formulated using Bioadhesive polymers which can adhere to epithelial surface 
in the stomach. Some of the most promising excipients that have been used 
commonly in these systems include polycarbophil, carbopol, lectins, chitosan, 
CMC and gliadin, etc. 
 
ii. Swelling systems: These are a type of non-floating gastroretentive drug delivery 
system which when enters stomach swells (due to presence of swellable 
polymers) to an extent that cannot pass through the pyloric sphincter leading to its 
retention in the stomach. 
 
iii. High density systems: These systems possess density greater than the gastric 
fluids due to which the system sinks to the bottom and remains in the stomach. 
These are formulated by coating drug on heavy inert materials like zinc oxide, 
titanium dioxide, iron powder, etc. 
 
iv. Expandable systems: These systems are capable of expanding and retain in the 
stomach for longer periods. These are usually formulated as a capsule containing 
dosage form in folded and compact form. After being exposed to stomach 
environment, capsule shell disintegrates and dosage form expands preventing its 
exit through the stomach. By using a suitable polymer, sustained and controlled 
drug delivery can be achieved. 
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Evaluation for gastro retention is carried out by means of 
 X-ray  
 Gamma scintigraphic monitoring of dosage form transit in the GI tract 
 
Generally manufactured marketed products
10
: 
Table 1: Generally manufactured marketed products: 
S.No Brand name Drug dose Company and 
country 
Remarks 
1 Valrelease Diazepam 15 mg Roche, USA Floating capsule 
2 Conviron Ferrous sulphate Ranbaxy, India Colloidal gel 
forming tablets 
3 Liquid gavison Aluminium 
hydroxide and mg. 
carbonate 
GlaxoSmithKli
ne, UK 
Effervescent 
Floating liquid 
alginate 
4 Topalkan Aluminium-
Magnesium antacid 
Pierre-Fabre, 
Drug 
Floating liquid 
alginate 
 
Polymers and Other Ingredients Used In preparations of Floating Drugs
11, 12 
The following types of the ingredients can be incorporated in to 
FDDS  
Hydrocolloids: Suitable hydrocolloids are synthethics, anionic or non-ionic like 
hydrophilic gumes, modified cellulose derivatives.  
Example: Acacia, pectin, agar, alginates, gelatin, casein, bentonite, veegum, 
HPMC K4 M, Calcium alginate, Eudragit S100, Eudragit RL, Propylene foam, Eudragit 
RS, ethyl cellulose, poly methyl methacrylate, Methocel K4M. 
Polyethylene oxide, β Cyclodextrin, HPMC 4000, HPMC 100, CMC, 
Polyethylene glycol, polycarbonate, PVA, Polycarbonate, Sodium alginate, HPC-L, CP 
934P, HPC, Eudragit S, HPMC, Metolose S.M. 100, PVP, HPC-H, HPC-M, HPMC K15, 
Polyox, HPMC K4, Acrylic polymer, E4 M and Carbopol can be used. 
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LITRATURE REVIEW 
1) Modi Foram P et al., 13   formulated and evaluated fixed dose combination moisture 
barrier film coated bilayer tablet of artesunate and amodiaquine hydrochloride. The 
tablets were prepared by dry granulation method for artesunate and wet granulation 
method for amodiaquine hydrochloride. The formula of amodiaquine hydrochloride 
was optimized using PVPK-30 as a binder. 
 
2) Durga Prasad Patnayak  et al.,14 prepared bilayer tablet formulation of metformin 
hydrochloride and glimepiride Two  different   matrix  formulations  were 
developed,  one  matrix  layer  with  hydrophilic  swellable  polymer  and another  
with hydrophobic polymer as carriers for sustained drug delivery from matrices  and  
were  evaluated. Hydroxypropylmethylcellulose and Polyethylene oxide  was  used  
as  polymers  in order to get the sustained release profile over a period of 24 h. 
Tablet s were evaluated for physical properties; drug  content   and  in vitro  drug  
release  were  compared  with standard  commercial  tablet s  (Glimy-M). The  
excipient s  used  in  this formulation  did  not  alter physicochemical  properties  of  
drug,  as  tested by  HPLC,  DSC,  and  FTIR.  Stability  of  the  drug  release  
profiles  at   6 months  in  40◦C  and  75%RH  suggesting  that   HPMC  based  
sustained release  formulation  was  stable  than  the  Polyethylene  oxide  sustained 
release formulation due to its stable and better targeting profile in terms of  drug  
release. 
 
3) Mina Ibrahim Tadros et al., 15   developed controlled-release effervescent floating 
matrix tablets of Ciprofloxacin hydrochloride with swelling, floating and adhesive 
properties. Ten tablet formulations were designed using HPMC K15M and/ or 
sodium alginate as release-retarding polymer(s) and sodium bicarbonate or calcium 
carbonate as a gas former. Swelling ability, floating behavior, adhesion period and 
drug release studies were conducted in 0.1N HCL (P
H 1.2
) at 37±0.5°c. The tablets 
showed acceptable physicochemical properties. Drug release profiles of all formulae 
followed non-Fickian diffusion. Statistical analyses of data revealed that tablets 
containing HPMC K15M (21.42%w/w), sodium alginate (7.14%w/w), and sodium 
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bicarbonate(20%w/w) (formula F7) or CaCO3 (20%w/w) (formula 10) were 
promising systems exhibiting excellent floating properties, extended adhesion 
periods and sustained drug release characteristics.  
 
4) Swain K et al., 16 developed controlled release Gastro retentive floating drug 
delivery system of Theophylline by employing response surface methodology. A 3
2
 
randomized full factorial design was developed to study the effect of formulation 
variables like various viscosity grades and contents of HPMC. The floating lag time 
for all nine experimental trial batches were less than 2 min and floatation time of 
more than 12 h. Theophylline release from the polymeric matrix system followed 
non-Fickian anomalous transport. Multiple regression analysis revealed that both 
viscosity and content of HPMC had statistically significant influence on all 
dependent variables. 
 
 
5) Muthukumaran M et al., 17 fabricated and evaluated of sustained release 
mucoadhesive bilayer tablets containing Nifedipine using the  Natural  Bioadhesive  
polymers  such  as  Pectin  to compare  the  synthetic  polymer  like  Carbopol  971-
P, HPMC-K4M  and  Polyvinyl  pyrrolidone  (PVP-  K30)  along  with  ethyl  
cellulose  and  magnesium stearate  as  an  impermeable backing layer to improve 
the oral bioavailability. The pre formulation study was performed by FTIR and DSC. 
The first layer which adheres to mucosa was obtained by direct compression of 
mucoadhesive polymers and drug. The second layer containing water impermeable 
agent was compressed on the first layer. The tablets were evaluated for weight 
variation, thickness, hardness, friability, surface pH, mucoadhesive strength, 
swelling index, in vitro drug release. The surface pH  of  all the  tablets  was  close to  
neutral  pH the  mechanism  of  drug  release  was found  to  be non-fickian  
diffusion. 
     
6) Mujoriya R Z et al., 18 developed and evaluated metoprolol succinate er and 
amlodipine besilate bilayer tablet by using different polymer (HPMC, Methocel, 
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Carbapol) with different diluents (MCC, Cellulose Phosphate, Starch, Croscarmalose 
Sodium) and then evaluated.  The experimental work was divided into 
Preformulation studies, formulation development and evaluation. Standardization of 
drug and excipients confirmed the authentication of the samples.  Thus it can be 
concluded that a stable bilayer tablet of Metoprolol succinate ER and Amlodipine 
besilate can be prepared by using HPMC K 15 M and carbomer as a polymer. It was 
found that the in vitro drug release of Metoprolol succinate ER was best explained 
by first order (r2 =0. 9994), as the plots showed the highest linearity, followed by 
Higuchi’s equation (r2 = 0.9974) and zero-order (r2 = 0.9471). 
 
 
7) Akash Yadav et al., 19 developed  a  bilayer  and  Floating-Bioadhesive  drug  
delivery  system exhibiting  a  unique  combination  of  floatation  and  bio adhesion  
to  prolong  residence  in  the  stomach  using propranolol hydrochloride as a model 
drug. The sustained layer was compressed and granules of the floating layer  were  
added  to  it  then  both  layers  were  compressed  using  a  single  station  rotary  
press. Hydroxypropyl  methylcellulose  (HPMC)  and  sodium bicarbonate were 
added to the floating layer and, when immersed in 0.1 mol/ l HCl, the tablet expands 
and rises to  the  surface  where  the  drug  is  gradually  released  without  
interference  from  gas  bubbles. The in vitro drug release from the  tablet  was  
controlled  by  the  amount  of  HPMC  in the  sustained  release  layer.  The floating 
ability of the tablets was studied. The  concentration  of  HPMC  significantly  
affects  the  drug  release  rate,  buoyancy  lag-time, detachment force and swelling 
characteristics of the tablets. The tablet was buoyant for up to 8 h. This kind of tablet 
exhibits independent regulation of buoyancy and drug release. 
 
8) Jain Jitendra et al., 20 was developed a bilayer-floating tablet (BFT) for 
Indomethacin using direct compression technology. Bilayer tablets were punched 
using optimized solid dispersion, HPMC K4M, Avicel PH-112, ac-di-sol, 
magnesium stearate and aerosil in fast release layer and optimized floating layer as 
sustained release layer. Tablets were evaluated for physic -Chemical properties such 
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as Hardness, Friability, Thickness, weight Variation and drug content uniformity. 
FT-IR studies are performed. In Vitro dissolution studies were carried out in a USP 
type II Paddle type apparatus. The optimized formulation (A2) showed no significant 
changes on stability studies when storing at 4º c, 40º c, /75%RH, 60ºc/80% RH for 3 
months. The release data obtained from the dissolution study of the bilayer tablets 
were analyzed with respect to first order model, Higuchi model, Korsmeyer-Peppas 
model, and zero order models. In this study optimized formulation (A2) release the 
drug up to 24hrs. 
9) Ajit Kulkarni et al., 21 prepared the regio-selective bilayer floating tablets of 
Atenolol and Lovastatin for biphasic release profile by direct compression technique. 
The bilayer floating tablets comprised of two layers, immediate release layer of 
sodium starch glycolate as a super disintegrant and the sustained release layer 
comprised of Hydroxy propyl methyl cellulose (HPMC) K100M and xanthan gum as 
the release retarding polymers. Sodium bicarbonate was used as a gas generating 
agent. All formulations formulated for more than 12 hours and released 90% of 
lovastatin within 30 min. Roentgenography was carried out to study the in vivo 
buoyancy of the optimized formulation and it was found to be buoyant for 8 hour in 
stomach. 
 
10) Ziyaur rahman et al., 22 developed the bilayer- floating tablets of captopril using 
direct compression method. The floating layer was formulated with HPMC K- grade 
(K4M, K15M and K100M) and effervescent mixture of citric acid and sodium 
bicarbonate. The sustained release layer comprised of captopril and various 
polymers such as HPMC- K15M, PVP-K30 and Carbopol 934p alone or in 
combination with the drug. Final formulation released approximately 95% of drug in 
24 hours in vitro, while the floating lag time was 10 min and the tablet remained 
floatable throughout the studies. Placebo formulation containing barium sulphate in 
the release layer administered to human volunteers for  in vivo X – ray studies 
showed that BFT had significantly increased the gastric residence time.   
11) Shweta sharma et al., 23 studied the formulation and evaluation of gastro-retentive 
floating matrix tablet of captopril. The floating tablets were prepared by direct 
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compression method using HPMC K4M, HPMC K15M and HPMC K100M. Sodium 
bicarbonate was used as a gas generating agent. The optimized formulation showed 
floating for more than 8 hours and retarded the release for more than 10 hours. 
 
12) Arunachalam.a et al.,24  prepared levofloxacin hemihydrate floating tablets by melt 
granulation method using the polymer, hydroxy propyl methyl cellulose (HPMC 
K100M) with different amounts and other excipients and sodium bicarbonate as gas 
generating agent. They developed a floatable drug delivery system of Levofloxacin 
hemihydrate for sustained drug delivery and gastric retentive property with special 
emphasis on optimization of formulations for floating matrix tablets. Levofloxacin 
floating tablet drug delivery system showed improved in-vitro bioavailability and 
extended drug release which may favour the reduced dose frequency and patient 
compliance. 
 
13) Venkata Srikanth Meka et al., 25 investigated the formulation of gastro retentive 
floating drug delivery system s (GRFDDS)of propranolol HCl by central composite 
design and to study the effect of formulation variables on floating lag time, D 1hr (% 
drug release at 1 hr.) and t90 (time required to release 90% of the drug). 3 factor 
central composite designs were employed for the development of GRFDDS 
containing novel semi synthetic polymer carboxymethylethyl cellulose (CMEC) as a 
release retarding polymer. CMEC, sodium bicarbonate and Povidone concentrations 
were included as independent variables. Optimized formulation was selected based 
on the criteria of less than 20 % of the drug release at 1 hr (fixed by USP dissolution 
conditions) and 90% of the drug released in between 10 to 11 hrs. 
 
14) Swati C. Jagdale et al., 26 developed a gastro-retentive drug delivery system of 
propranolol hydrochloride. The ability of various polymers to retain the drug when 
used in different concentrations was investigated. Hydroxypropyl methylcellulose 
(HPMC) K4 M, HPMC E 15 LV, Hydroxypropylcellulose (HPC; Klucel HF), 
xanthan gum, and sodium alginate (Keltose) were evaluated for their gel-forming 
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abilities. The bioavailability of propranolol increases in presence of food. Also, the 
absorption of various drugs such as propranolol through P-glycoprotein (P-gp) efflux 
transporter is low and erratic. They were evaluated for physical properties, in vitro 
release as well as in vivo behavior. In preliminary trials, tablets formulated with 
HPC, sodium alginate, and HPMC E 15 LV failed to produce matrix of required 
strength, whereas formulation containing xanthan gum showed good drug retaining 
abilities but floating abilities were found to be poor. Finally, floating tablets were 
formulated with HPMC K4 M and HPC. 
 
15)  Arun Prasad K et al., 27 formulated solid dispersion tablet of Terbinafine 
Hydrochloride using carriers polyethylene glycol 6000 (by melting  method)  and  
polyvinyl  pyrrolidone  K  30  (by  solvent  method)  in  the  drug  carrier  ratio  of  
1:1,  1:2  and  1:3.  The prepared solid dispersions were characterized for their drug 
content, thermal studies, infrared spectral studies, differential scanning calorimetric 
studies, aqueous solubility studies and in-vitro release studies. As a result solid 
dispersion formulation showed improved dissolution rate than pure drug and 
physical mixture. The solid dispersion showing better release profile was chosen to 
formulate into a tablet dosage form of weight 600 mg. The tablets compressed were 
evaluated for its physical parameters. The dissolution profile of formulated tablet 
was compared with the marketed product and the formulated tablet showed better 
release profile than the marketed product. 
 
16) Ganesh Chaulang et al., 28 enhanced the dissolution profile of furosemide using 
solid dispersion (SD) with crospovidone (CPV) by kneading technique. 1:1 (w/w) 
and 1:2 (w/w) solid dispersions were prepared by kneading method using solvent 
water and ethanol in 1:1 ratio. Dissolution studies using the USP paddle method 
were performed for solid dispersions of furosemide at 37 ± 0.5
o
C and 50 rpm in 
simulated gastric fluid (SGF) of pH 1.2. Fourier transformer infrared (FTIR) 
spectroscopy, differential scanning calorimetry (DSC), and x-ray diffractometry 
(XRD) were performed to identify the physicochemical interaction between drug and 
carrier, hence its effect on dissolution. Tablets were compared with commercial 
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products. Dissolution of furosemide improved significantly in solid dispersion the 
1:2 solid dispersion indicated increase in dissolution 5.11 fold. Tablets containing 
solid dispersion exhibited better dissolution profile than commercial tablets. 
 
17) S Vidyadhara et al., 29 prepared Solid dispersions of Glimepiride with sodium 
starch glycolate (SSG) and further compressed as tablets using diluents such as 
lactose, dicalcium phosphate and microcrystalline cellulose. The solid dispersions of 
Glimepiride with SSG at different ratios were prepared by physical mixing, solvent 
evaporation and kneading methods. The rapid release of poorly soluble Glimepiride 
from solid dispersions was influenced by the proportion of polymer and the method 
employed for its preparation. The solid dispersions exhibit faster dissolution 
characteristics as compared to plain drug. This was due to solubilizing effect of 
carrier or crystallization of drug entrapped in molecular state by the carrier. A higher 
dissolution rate was obtained with solid dispersions prepared by solvent evaporation 
method and kneading method in the ratio of 1:2 for the drug and SSG. 
 
 
18) K P Chowdary et al., 30 formulated and evaluated etoricoxib solid dispersion using 
starch phosphate, PVP and PEG 4000 by factorial design for enhancing the 
dissolution rate and efficiency of etoricoxib, a BCS class II drug. The individual 
main and combined effects of the three factors namely starch phosphate (factor A), 
PVP K- 30 (factor B) and PEG 4000 (factor C) in enhancing the dissolution rate and 
dissolution efficiency of etoricoxib were evaluated in a 23- factorial study. DE30 
was also increased from 3.03% for etoricoxib pure drug to 55.28, 46.36 and 36.61 % 
respectively with solid dispersions. Addition of PVP and PEG 4000 to the solid 
dispersions in starch phosphate has further increased the dissolution rate upto 200.59 
fold and dissolution efficiency upto 29.15 fold.   
 
19) Anusha P et al., 31 developed and evaluated Drotoverine taste masked tablets with 
improved dissolution efficiency using solid dispersion technique. The purpose of his 
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research work is to mask the bitter taste of the drug and formulate the taste masked 
solid dispersion of the drug into tablets by direct compression method. Solid 
dispersion prepared by using urea and mannitol by melting / fusion method. An In 
vitro release study also performed. In addition to taste masking the tablets exhibits 
better dissolution profile. 
 
 
20) Sharmi Islam et al., 32 studied the enhancement of dissolution rate of gliclazide 
using solid dispersion method. The solid dispersion prepared by using poloxamer by 
solvent evaporation method. The solid dispersions are evaluated for the drug loading 
and dissolution behavior and were found effective to enhance the solubilty of 
gliclazide in dissolution medium significantly.   
 
21) Panikkarakayil Habeeb et al., 33 formulated, optimized and evaluated solid 
dispersion tablets of aceclofenac using Kollidon 30. From this study they evaluated 
the effect of polyvinyl pyrrolidone on dissolution enhancement of aceclofenac from 
solid dispersion both by invitro and invivo methods. Aceclofenac solid dispersion 
exhibited considerable increase in the solubility in comparison with the pure drug in 
7.4 pH phosphate, methanol, isopropyl alcohol and acetone. It is noted that the 
quantity of the carrier have considerable effect in the solubility of the drug in the 
solid dispersion. It is concluded that the dissolution of aceclofenac can be enhanced 
by the use of hydrophilic carrier like PVP.  
 
 
22)   D V Pawar et al., 34 formulated and evaluated controlled release matrix tablet with 
solid dispersion granules of aceclofenac. The tablets were prepared by direct 
compression method using polymers like HPMC, Carbopol 934(CP). This 
formulation contains 25% of HPMC has complete release of 24 hours as well as CP 
containing formulations showed concentration dependent rate of drug release. It is 
clarified that solid dispersion granules was one of the promising controlled release 
system applying solid dispersion technique for the poorly water soluble drug.   
Literature review 
 
Department of pharmaceutics, Madras Medical College. Page 31 
 
 
23) Abdul Althaf S et al., 35 formulated and evaluated the bilayer immediate release 
tablets of clopidogrel biphosphate   and aspirin. This study was intended to produce 
an immediate release bilayer tablets using solid dispersion technique. The prepared 
tablets were evaluated for the dissolution. The dissolution followed zero order 
kinetics as it is independent of concentration. Fusion method was employed for 
preparing solid dispersion as it improves safety and efficacy and intern improves its 
bioavailability. Formulations F2, F3, F4 were taken to study the effect of 
superdisintegrants like sodium starch glycolate, crospovidone, Croscarmalose 
sodium respectively.   6% superdisintegrants concentration showed better release 
profile compared with other concentrations. 
 
 
24) Pankaj Nainwal et al., 36. performed a comparative solubility enhancement study of 
rosuvastatin using solubilization techniques Solid dispersion of Rosuvastatin was 
prepared by solvent evaporation method; PEG (Polyethylene glycol) 4000, mannitol 
and urea were used as carriers. The solubility enhancement of Rosuvastatin   by 
different solubilization technique   was   observed   in   decreasing   order   as   
hydrotropic   solubilization   >   solid   dispersion   > Micellar   solubilization.   It   
was   observed   that   the   solubility   increased   with   the   increase   in   the 
concentration of hydrotropic agents and amongst the various hydrotropic agents used 
the solubility was Rosuvastatin was enhanced greatest to 55 folds with sodium 
salicylate. 
 
25) S H Lakade et al., 37 formulated and evaluated sustained release matrix tablet of 
Anti-anginal drug. The objective of study was the development of hydrophilic 
polymer (HPMC) and hydrophobic (EC) based nicorandil matrix sustained release 
tablet which can release the drug upto time of 24 hours in predetermined rate. The 
in-vitro release rate profile should the higher concentration of F2 polymer in tablet, 
the combination of hydrophilic and hydrophobic combination showed less result 
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than use of alone. The in–vitro release data was well fit to Peppas and Hixon crowel 
release kinetics.  
 
26)  Patel R et al., 38optimized propranolol hydrochloride controlled release matrix 
tablet by using factorial study design prepared by direct compression 
technique.Hydroxypropylmethylcellulose K15M, (HPMC K15M) and Carbopol 
934P were used in formulating the matrix tablets.  The results indicate that batch F7 
showed the highest value among all the batches. It was observed that the blending 
ratio of HPMC K15M-Carbopol 934P and polymer concentration have distinct effect 
on in-vitro drug release profile. Release rate of Propranolol hydrochloride decreased 
proportionally with increased in concentration of Carbopol 934P and total polymer 
concentration. 
 
27) Kiran Chaturvedi et al., 39formulated and performed invitro evaluation of 
propranolol floating matrix dosage form developed by direct compression method 
using citric acid and sodium bicarbonate as the effervescent base. Hydroxypropyl 
methylcellulose; HPMC K15M was used to prepare the floating tablets to retard the 
drug release for 12h in stomach. Na-carboxy methyl cellulose (NaCMC) or carbopol 
934P was added to alter the drug release profile or the dimensional stability of the 
formulation. Formulations were evaluated for floating lag time, duration of floating, 
dimensional stability, drug content and in vitro drug release profile. Formulation F5 
containing a combination of carbopol and HPMC was able to maintain a firm matrix, 
showed good water uptake and was able to sustain the drug release and only 87.16% 
drug was released at the end of 12 h.  
 
 
28) Nitya Sri Valli Ruthraraju et al., 40 prepared rosuvastatin  calcium nanoparticles by  
top  down  and  bottom  up  techniques;  the  top  down technique  produced  
particles  in  the  nanometer  size  range  of  below  1000nm.  The Nano crystal 
formulations F-3, F-4, F-5 prepared by top down technique using polymeric and 
surfactant stabilizers shows that particles size was within the nanometer range. 
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Formulations containing PVP,  SLS,  Poloxamer  188,  Tween  80:  PVP,  and  
Tween  80: HPC  as  polymeric  and  surfactant  stabilizers  were  prepared  and 
compared. HPC and HPMC containing formulations were found to give better 
release of drug.   
 
29) Shaimaa N Abd Al Hammid et al., 41 developed Orodispersible  tablets of  
Rosuvastatin  using  different  types  of  superdisintegrants  to  enhance  the 
disintegration and dissolution of Rosuvastatin to improve bioavailability of the drug. 
Formulas prepared by direct compression showed good flowability, while formulas 
prepared by wet granulation showed very poor flow properties. Various 
superdisintegrants were used including Croscarmalose (CCS), sodium starch 
glycolate (SSG) and crospovidone (CP), the latter found to be the best in term of 
showing the fastest disintegration time. 
 
30) Shantveer V  Salger et al., 42 prepared and evaluated sustained release matrix 
tablets of propranolol hydrochloride. Hydroxypropyl methyl cellulose K100M used 
as a rate retarding polymer whereas lactose and dibasic calcium phosphate are used 
as diluent. The effects of the proportion of the  polymer  and  the  influence  of  co-
excipients  like  lactose  and  dibasic  calcium phosphate  on  the release  rate  of  
drug  was  investigated. The dissolution t50% and t90%values for the co-excipients 
were in the order of lactose>dibasic calcium phosphate. On conclusion The  drug-
polymer  ratio  was  found  to influence  the  release  of  drug  from  the 
formulations.  As the polymer level is increased, the drug release rates were found to 
be decreased.  
31) Shivanand Pandey et al., 43 formulated and evaluated Gastro  retentive  tablets  of  
propranolol  hydrochloride  by  direct  compression method  using  citric  acid  and  
sodium  bicarbonate  as the  effervescent  base.  Hydroxypropyl methylcellulose; 
HPMC K15M was used to prepare the floating tablets to retard the drug release for 
12h in stomach. Formulations were evaluated for floating lag time, duration of 
floating, dimensional stability, drug content and in vitro drug release profile. The 
formulations were found to  have  floating  lag  time  less  than  1min. Drug  releases  
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were  slow  from  formulations  F2,  F3  and  F5  and  the  release  of  drug  from  
them were found to be 80.66% ± 1.96%, 79.11%± 2.322% and 87.16% ± 2.377% 
respectively. 
32) Shalini Gupta et al., 44 formulated Rosuvastatin  Calcium tablets using  sodium  
starch  glycolate  as  super-disintegrant  and  Dibasic-Calcium  Phosphate  used  as  
stabilizing agent.  Tablets were  evaluated  by  different  parameters  such  as  
thickness,  hardness,  friability,  weight  variation,  In-vitro  dissolution  studies, 
content  of  active  ingredient,  stability  studies  and  FT-IR  studies  .The  evaluated  
property  of  the  finished product  complies  with  the  In-house specification.  In  
vitro  release  from  the  formulation  was  studied  as  USP  dissolution  procedure.  
The formulation gave an immediate release effect. The Stability Study of optimized 
batch was carried out for one month as per ICH guidelines and no changes were 
found. They were concluded that tablet of Rosuvastatin 10 mg suited for therapy 
anti-hyper-lipidemic. 
 
33) Vidyadhara S et al.,45  made an attempt  to enhance the solubility, dissolution rate 
and oral bioavailability of poorly soluble rosuvastatin by formulating rosuvastatin 
calcium as solid dispersions using various techniques with polyethylene glycol 
(PEG) 6000 as a carrier. Fast dissolving tablets of rosuvastatin were prepared with 
super disintegrants like sodium starch glycolate, Croscarmalose sodium, 
pregelatinized starch and mannitol from the optimized solid dispersions. Tablets 
were evaluated for physical parameters and drug release by in vitro dissolution 
studies. Surface characteristics, drug-excipient interactions and crystal morphology 
of optimized solid dispersions were evaluated by SEM analysis, DSC and XRD 
studies, respectively. 
 
34) KPR Chowdary et al.,46   prepared  and  evaluated  solid  dispersions  of 
aceclofenac  in  combined  carriers,  a  water  dispersible  new  modified  starch  
namely  starch phosphate  and  a  water  soluble  surfactant  namely  Gelucire  50/13  
for  enhancing  the  dissolution rate and dissolution efficiency of aceclofenac in a 2
2
 
factorial study. 
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PATENTS IN FDDS: 
Table: Patents on floating drug delivery systems. 
S.No Type of formulation  Patent number 
1 Gastro retentive dosage form U.S- 7413752 
2 Multiple unit floating dosage form  EP- 10697 
3 Bilayer floating tablet EP-002445 
4 Floating tablet U.S-6635279 
5 Floating microspheres U.S-6207197 
6 3- Layer floating tablets U.S-5780057 
7 Floating device U.S-4055178 
8 Floating capsule U.S-4126672 
9 Empty globular shells U.S-3976164 
10 Floating granules U.S-4844905 
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AIM AND PLAN OF WORK 
THREE MAIN CONCEPTS  
 Sustaining the action of Propranolol hydrochloride by gastroretentive (Regio-
selective) floating technology to avoid repeated dosing.  
 Improvement of solubility of poorly soluble Rosuvastatin calcium, BCS Class II drug 
by solid dispersion technique. 
 Regio-selective floating bilayer tablet technology for combined administration of both 
the drug.  
AIM OF PROJECT WORK 
A. The main objective of the present study is to develop Regio-selective bilayer floating 
tablets containing propranolol hydrochloride as sustained release layer and 
Rosuvastatin calcium as immediate release layer for coronary heart disease related 
events.  
B. Hypertension and hypercholesterolemia are the two leading risk factors for heart 
disease; these two together cause an increase in coronary heart disease related events.  
C. To provide an effective, safe and stable pharmaceutical oral formulation containing 
both immediate release and sustained release of two drugs with different mechanism 
of action β blockers and HMG Co-A Reductase inhibitor were used. Nowadays β 
blockers are the most extensively used class of agents in the treatment of congestive 
heart failure (CHF). The HMG Co-A Reductase inhibitor have been widely used as 
anti hyperlipidemic drug. 
D. Improvement of solubility of poorly soluble drug Rosuvastatin calcium by solid 
dispersion with starch phosphate. 
E. To prepare Propranolol Hydrochloride SR Layer to avoid repeated dosing and to 
investigate the effect of the polymer and the polymer concentration on drug release. 
PLAN OF WORK 
 Preformulation studies. 
 Raw material analysis  
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 Physical and chemical compatibility studies  
 Construction of Calibration curve. 
 Precompression studies of drug and blends. 
 Bulk density  
 Tapped density  
 Angle of repose  
 Carr’s index  
 Hausner’s ratio  
 Preparation of Starch phosphate.  
 Formulation of Starch phosphate  Solid dispersion 
 FTIR spectroscopic study of solid dispersion 
 Formulation of immediate release (IR) Solid dispersion compressed tablets. 
 Determination of drug content of Rosuvastatin solid dispersion 
 Physical compatibility and FTIR chemical compatibility studies  
 Dissolution studies of Rosuvastatin solid dispersion   
 Post compression studies of IR tablets for physical parameters like 
 Physical appearance 
 uniformity of weight  
 hardness, thickness, diameter 
 friability 
 determination of drug content of IR  tablets 
 Disintegration studies of IR tablets. 
 Invitro dissolution studies of IR tablets. 
  
 Formulation of sustained release granules. 
 Post compression studies of SR tablets for physical parameters like 
 Physical appearance 
 Hardness, Thickness, Diameter and Friability 
 Determination of drug content of SR tablets  
 Uniformity of weight 
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 Evaluation of floating characteristics of SR tablets- Buoyancy test. 
 Invitro dissolution studies of SR tablets. 
 Formulation of bilayer floating tablets (BFT). 
 Post compression studies of bilayer floating tablets like    
 Determination of drug content 
 Uniformity of weight 
 Hardness, thickness, diameter and friability 
 Evaluation of floating characteristics of bilayer floating tablets 
 Evaluation of release kinetics of BFT 
 Stability studies of prepared tablets as per ICH guideline. 
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RATIONALE OF STUDY 
    Rationale of selection of Propranolol hydrochloride as SR Floating layer
47
: 
 Propranolol, a non-selective beta adrenergic blocking agent, has been widely used 
in the treatment of hypertension, angina pectoris, and many other cardiovascular 
disorders.  
 It is highly lipophilic and is almost completely absorbed after oral administration. 
However, much of the drug is metabolized by the liver during its first passage 
through the portal circulation.   
 On an average, only about 25% reaches the systemic circulation. Its elimination 
half-life is also relatively short (about 2–6 h). 
 It shows pH dependent solubility; solubility at pH 1.2 is 225 mg/ml, while at pH 
6.8 it is 130mg/ml. In addition, the drug is stable at acidic pH only; decomposes 
rapidly when alkaline. Solutions are most stable at pH 1.2; in aqueous solutions, 
propranolol decomposes with oxidation of the isopropylamine side-chain.  
 A conventional tablet of propranolol hydrochloride contains a dose of 20 to 40 mg 
and used 3 to 4 times a day in the management of several cardiovascular disorders 
such as hypertension, angina pectoris and arrhythmias. Such frequent drug 
administration may reduce patient’s compliance and therapeutic efficacy. 
 The present study is to formulate floating tablet containing Propranolol 
hydrochloride in the SR layer to increase bioavailability and to avoid repeated 
dosing. 
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Rationale of selection of Rosuvastatin calcium as immediate release SD layer 
48, 49, 50,52
: 
 Rosuvastatin, as rosuvastatin calcium is a HMG-CoA reductase inhibitor used for 
the treatment of dyslipidaemia with absolute bioavailability of 20%, it is about 
88% bound to plasma proteins. 
 Rosuvastatin calcium belongs to BCS CLASS II drug which is water insoluble or 
poorly soluble and shows poor bioavailability. 
 In order to increase its solubility, solid dispersion of the drug is prepared. 
 Rosuvastatin (10–40 mg) monotherapy decreased LDL-C by 53% and raised 
HDL-C by 7% 
 One of the first studies establishing clinical efficacy and superiority of 
rosuvastatin over other commonly used statin agents was the Statin Therapies for 
Elevated Lipid Levels Compared across Doses to Rosuvastatin (STELLAR) 
study. 
 Across the range of doses, rosuvastatin reduced LDL-C by 8.2% more than 
atorvastatin, 26% more than pravastatin, and 12%–18% more than simvastatin (p 
< 0.001). Milligram-equivalent LDL-C reduction was greater with rosuvastatin 
than all other statins (p < 0.002). Rosuvastatin also reduced TC more significantly 
than all other statins (p < 0.001) and decreased TG more significantly (p < 0.001) 
than simvastatin and pravastatin. Similarly, rosuvastatin increased HDL-C by a 
mean of 7.7%–9.6% compared to 2.1%–6.8% in all other groups. 
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  Rationale of selection of propranolol hydrochloride and rosuvastatin calcium for Regio-
selective bilayer floating tablet
52 
 Beta-blockers and statins are individually associated with reduced mortality in 
patients undergoing noncardiac, nonvascular surgery. 
 Study provides evidence that β-blockers and statins are associated with a 
reduction of perioperative mortality in patients undergoing noncardiac, 
nonvascular surgery.  
 Hypertension and dyslipidemia are conditions that can coexist frequently. 
National Health and Nutrition Examination Survey (NHANES III) has shown that 
64% of patients with hypertension also have dyslipidemia and conversely, 
approximately 47% of patients with dyslipidemia have hypertension. 
Hypertension and hypercholesterolemia are the two leading risk factors for heart   
disease; these two together cause an increase in coronary heart disease related 
events. 
 Hence regio selective floating bilayer tablets of propranolol hydrochloride as 
sustained release layer and rosuvastatin calcium as solid dispersion compressed 
immediate release layer was formulated to reduce the repeated dosing frequency 
of propranolol hydrochloride,  improved solubility  of rosuvastatin calcium and 
improve the patient compliance.  
 Thus regio-selective bilayer floating tablets of propranolol hydrochloride and 
rosuvastatin calcium was more beneficial for hypertensive patients  
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DISEASE PROFILE 
HYPERTENSION
53, 54, 55
:  
          Hypertension is defined as the condition in which the arteries have persistently 
elevated blood pressure. Arteries are the blood vessels that carry oxygenated blood from 
the heart to the blood tissues. 
EPIDEMIOLOGY 
           Hypertension is one of the leading causes of the global burden of disease. 
Approximately 7.6 million deaths (13–15% of the total) and 92 million disability-
adjusted life years worldwide were attributable to high blood pressure in 2001. 
Hypertension doubles the risk of cardiovascular diseases, including coronary heart 
disease (CHD), congestive heart failure (CHF), ischemic and hemorrhagic stroke, renal 
failure, and peripheral arterial disease. 
 It often is associated with additional cardiovascular disease risk factors, and the 
risk of cardiovascular disease increases with the total burden of risk factors. Although 
antihypertensive therapy clearly reduces the risks of cardiovascular and renal disease, 
large segments of the hypertensive population are either untreated or inadequately 
treated. 
Both environmental and genetic factors may contribute to regional and racial 
variations in blood pressure and hypertension prevalence. Studies of societies undergoing 
"acculturation" and studies of migrants from a less to a more urbanized setting indicate a 
profound environmental contribution to blood pressure. Obesity and weight gain are 
strong, independent risk factors for hypertension.  
It has been estimated that 60% of hypertensives are >20% overweight. Among 
populations, hypertension prevalence is related to dietary NaCl intake, and the age-
related increase in blood pressure may be augmented by a high NaCl intake. Low dietary 
intakes of calcium and potassium also may contribute to the risk of hypertension. Alcohol 
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consumption, psychosocial stress, and low levels of physical activity also may contribute 
to hypertension. 
Criteria for diagnosis 
Category Systolic 
(mmHg) 
Diastolic 
(mmHg) 
Optimal blood pressure <120 <80 
Normal blood pressure <130 <85 
High normal blood pressure 130-139 85-89 
Hypertension stage 1(mild) 140-149 90-99 
Hypertension stage 2(moderate) 160-179 100-109 
Hypertension stage 3(severe) ≥180 ≥110 
CLASSIFICATION: 
Primary hypertension  
It is also called essential or idiopathic hypertension, affects 90-95% of hypertensive 
individuals. The causes include genetic and environmental factors. 
Secondary hypertension  
It is caused by another medical condition or treatment. Their cause includes kidney 
problems, adrenal gland tumors, thyroid disease and narrowing of aorta. 
RISK FACTORS: 
FOR PRIMARY HYPERTENSION: 
 Family history   
 High intake of sodium and fat 
 Sedentary life style 
 Obesity, stress 
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 Excessive alcohol consumption 
FOR SECONDARYHYPERTENSION: 
 Renal Artery disease 
 Mineral deficiencies(calcium, potassium, magnesium) 
 Brain tumour , quadriplegia, head injury 
 Thyroid, pituitary or parathyroid dysfunction. 
 
PATHOPHYSIOLOGY: 
  The exact cause of hypertension is unknown. Arterial Blood Pressure is a 
product of cardiac output and peripheral resistance. Peripheral resistance is increased by 
factors that increase blood viscosity or reduce the lumen size of vessels. 
           Mechanisms leading to hypertension are  
 Changes in the arteriolar blood causing increased peripheral vascular 
resistance. 
 Increased blood volume resulting from renal or hormonal dysfunction. 
 Arteriolar thickening caused by genetic factors leading to increased 
peripheral resistance. 
 The rennin angiotensin aldosterone system along with  abnormalities in renal 
tubules also plays a part. 
 Increased circulatory blood volume and increased peripheral                 
 Resistance is main pathophysiological mechanisms. 
SIGNS AND SYMPTOMS: 
 Headache, some quite severe 
 Dizziness 
 Fatigue 
 Irregular heart beat  
 Confusion 
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 Vision problems 
 Chest pain  
 Nocturia 
 
DIAGNOSIS: 
 Blood pressure measurements show elevation. 
Blood chemistry reveals elevated blood urea nitrogen and serum. 
 Creatinine levels suggestive of renal disease or hypokalaemia indicating 
adrenal dysfunction. 
 Chest X-ray shows cardiomegaly. 
 Urine analysis shows protein, casts, red blood cells, white blood cells 
suggesting renal disease. 
 Electrocardiography detects left ventricular hypertrophy or ischemia. 
 Echocardiography reveals left ventricular hypertrophy. 
 TREATMENT: 
     Lifestyle modification to reduce risk factors 
 Diuretics 
 Angiotensin converting  enzymes (ACE)inhibitors 
 Alpha adrenergic receptor blockers 
 Beta adrenergic receptor blockers 
 Calcium channel blockers 
 Central adrenergic inhibitors 
 Vasodilators 
DYSLIPIDEMIA 
56, 57
:
 
 
DEFINITION: 
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Dyslipidemia is an abnormal amount of lipids (cholesterol and / or fat) in the 
blood. In developed countries, most dyslipidemias are hyperlipidemias; that is an 
elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation 
of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc 
transferase (OGT) may cause dyslipidemia. 
          Increase       Decrease 
LIPID  Hyperlipidemia : 
- Hypercholesterolemia: due to 
defect of chromosome 19. 
- Hyperglyceridemia: glycerides. 
- Hypertriglyceridemia: 
triglycerides 
 Hypolipidemia 
 hypercholesterolemia 
LIPOPROTEIN  hyperlipoproteinemia: 
lipoprotein (usually LDL) 
 hyperchylomicronemia 
chylomicrons 
 hypolipoproteinemia: 
lipoprotein 
 abetalipoproteinemia: β-
lipoprotein 
 tangier disease: HDL 
BOTH Combined hyperlipidemia: both 
LDL and triglycerides 
 
 
 
HYPERLIPIDEAMIA 
The lipids of human plasma are transported in macromolecular complexes termed 
lipoproteins. A number of metabolic disorders that involve elevations in levels of any of 
the lipoprotein species are thus termed hyperlipoproteinemias or hyperlipidemias. Term 
hyperlipidemia denotes increased levels of triglycerides in plasma. Hyperlipidemia is a 
major cause of atherosclerosis and atherosclerosis- associated conditions such as 
coronary heart disease (CHD), ischemic cerebrovascular disease and peripheral vascular 
disease. 
Hyperlipidemia (elevated levels of triglycerides or cholesterol) and a reduced 
HDL-C level occurs as a consequence of several interrelated factors that affect the 
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concentrations of the various plasma lipoproteins. These factors may be lifestyle or 
behavioral (diet or exercise), genetic (mutations in gene regulating lipoprotein levels) or 
metabolic (diabetes mellitus) or other conditions that influence plasma lipoprotein 
metabolism. 
Lipoprotein transport in the blood  
Lipids and cholesterol are transported through the blood as macromolecular 
complexes of lipid and protein known as lipoproteins. These consist of a central core of 
hydrophobic lipid (triglycerides and cholestryl esters) encased in a more hydrophilic coat 
of polar substances- phospholipids, free cholesterol and associated apolipoproteins. There 
are four main classes of lipoproteins differing in relative proportion of the core lipids and 
in the type of apoprotein. They differ on the basis of their size and density. 
 They are classified into:  
1. High density lipoproteins (HDL) 
2. Low density lipoproteins (LDL) 
3. Very Low density lipoproteins (VLDL) 
4. Chylomicrons  
Each of this lipoprotein classes has a specific role in lipid transport in the 
circulation and there are different pathways for exogenous and endogenous lipids. In the 
exogenous pathway cholesterol and triglycerides are absorbed from the gastrointestinal 
tract and transported in the lymph and then in the plasma as chylomicrons (diameter 100-
1000nm) to muscle and adipose tissue. Here the cores of chylomicrons are hydrolyzed by 
lipoprotein lipase and the tissues take up the resulting free fatty acids.  
 
The chylomicron remnants (30-50nm), still containing their full complement of 
cholestryl esters pass to the liver, bind to the receptors on hepatocytes and undergo 
endocytosis. Cholesterol is liberated within the liver cell and may be stored, oxidized to 
bile acids or secreted in the bile unaltered. Alternatively, it may enter the endogenous 
pathway of lipid transport in VLDL. 
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In the endogenous pathway cholesterol and newly synthesized triglycerides are 
transported from the liver as VLDL (30-80nm) to muscle and adipose tissues where the 
triglycerides are hydrolyzed and the resulting fatty acids enter the tissues. During this 
process the lipoprotein particles become smaller (20-30nm) but still have a full 
complement of cholestryl esters and ultimately become LDL, which provides the source 
of cholesterol for incorporation into cell membranes and for synthesis of steroids and bile 
acid. 
ETIOLOGY: 
 Primary and secondary causes contribute to dyslipidemia. 
PRIMARY CAUSES: 
 Primary causes are single and multiple gene mutations that result in either 
overproduction or defective clearance of TG and LDL cholesterol or in underproduction 
or excessive clearance of HDL. 
SECONDARY CAUSES: 
 Secondary causes contribute to most cases of dyslipidemia in adults. The most 
important secondary cause in developed countries is a sedentary lifestyle with excessive 
dietary intake of saturated fat, cholesterol and transfats. 
 Diabetes is an especially significant secondary cause because patients tend to 
have an atherogenic combination of high TGs; high small, dense LDL fractions; and low 
HDL (diabetic dyslipidemia). Patients with type 2 diabetes are especially at risk. 
SIGNS AND SYMPTOMS: 
 Dyslipidemia itself usually causes no symptoms but can lead to 
symptomatic vascular diseases   including coronary artery disease (CAD) 
and peripheral arterial disease. 
 High levels of TGs (>1000mg/dL) can cause acute pancreatitis. 
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 High levels of LDL can cause eyelid xanthelasmas; arcuscorneae; and 
tendinous xanthomas at       the Achilles, elbow and knee tendons and over 
metacarpophalangeal joints.  
 Severe hypertriglyceridemia (>2000mg/dL) can give retinal arteries a 
creamy white appearance (lipemiaretinalis). 
 Extremely high lipid levels give a lactescent (milky) appearance to 
plasma. 
 Symptoms include Parasthesias, Dyspnea and Confusion. 
DIAGNOSIS: 
 Diagnosis is by measuring plasma levels of total cholesterol, TGs and 
individual lipoproteins. 
 LDL cholesterol values are more often calculated as the amount not 
contained in HDL and VLDL. VLDL is estimated by TG ÷ 5 because the 
cholesterol concentration in VLDL particles is usually 1/5 of the total lipid 
in the particles. 
 Thus LDL Cholesterol= TC-[HDL C+ (TG ÷ 5)]. 
Classification of plasma lipid levels  
Total cholesterol 
<200mg/dl   Desirable 
200-239mg/dl    Borderline high 
>240mg/dl   High 
High density lipoprotein- Cholesterol  
<40mg/dl   Low 
>60mg/dl   High  
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Low density lipoprotein- Cholesterol 
<100mg/dl   Optimal 
100-129mg/dl   Near optimal 
130-159mg/dl   Borderline high  
160-189mg/dl   High 
>190mg/dl   Very high 
Triglycerides  
<150mg/dl   Normal 
200-499mg/dl   Borderline high  
200-499mg/dl   High 
>500mg/dl   Very high 
SCREENING: 
 A Fasting lipid profile (TC, TG, HDL-C and LDL-C) should be obtained in all 
adults ≥ 20 years and should be repeated every five years. 
MANAGEMENT: 
 The main goal of dyslipidemia management is to maintain blood cholesterol level 
within the normal range as possible.  
 Lifestyle modification focusing on the reduction of saturated fat and cholesterol 
intake. 
 Weight loss.  
 Increased physical activity. 
 Smoking cessation. 
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TREATMENT: 
DRUGS- FOUR CLASSES OF LIPID LOWERING DRUGS ARE 
 HMG CoA reductase inhibitors ( statins ) 
 Fibrates (gemfibrozil, clofibrate, fenofibrate). 
 Niacin (nicotinic acid). 
 Bile acid binding resins( colestipol, cholestyramine) 
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DRUG PROFILE 
PROPRANOLOL HYDROCHLORIDE
58
 
Chemical structure 
Propranolol 
.HCl 
 
 
Molecular formula    : C16H21NO2.HCL 
Molecular weight    : 259.34 g/mol 
Chemical name    : (RS)-1-(1-methylethylamino)-3-(1-
naphthyloxy) 
       Propan-2-ol    
Characters 
Appearance               : White or almost white, crystalline powder, 
slightly  
                                                                        Hygroscopic 
Solubility                                                   : Freely soluble in water, sparingly soluble 
in alcohol 
Loss on drying             : 0.2634% 
Melting point                                            : 165.5
0
C 
Sulphated ash              : 0.0224% 
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Pharmacokinetics
59
 
 Absorption    :  Propranolol is almost completely absorbed 
from the GI tract; however, plasma concentrations attained are quite variable 
among individuals. Rapidly absorbed, peak plasma concentration within 2 
hours (conventional tablet);  5hours (modified release) 
 Protein binding   :   More than 90% 
 Metabolism   : Propranolol is extensively metabolized 
with most metabolites appearing in the urine 
 Half-life    :  4 hours 
 Excretion    :  Via urine mainly as metabolites. 
Mechanism of action 
 Propranolol competes with sympathomimetic neurotransmitters such as 
catecholamine for binding at beta β (1)-adrenergic receptors in the heart, 
inhibiting sympathetic stimulation.  
 This results in a reduction in resting heart rate, cardiac output, systolic and 
diastolic blood pressure, and reflex orthostatic hypotension. 
 Adverse reactions  
Symptoms of overdose include bradycardia, cardiac failure, hypotension, and 
bronchospasm. LD50=565 mg/kg (orally in mice). 
Dosage     : Oral- 10 mg BD to 160 mg QID thrice 
daily. 
         i.v   - 2 to 5 mg injected over 10 mins with 
constant 
                                                                Monitoring 
Contra indications    : Contraindicated in pregnancy, lactation, 
hypersensitivity. 
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Administration    : Taken with food  
Therapeutic indications   : Anti-anxiety, Antihypertensive and 
Adrenergic drug      Adrenergic β -Antagonists, 
Vasodilator  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug profile 
 
Department of Pharmaceutics, Madras Medical College. Page 55 
 
Rosuvastatin calcium
58,60
 
Chemical structure 
 
            
 
 
 
 
Molecular formula    : (C22H27FN3O6S) 2Ca 
Molecular weight    : 1001.14 g/mol 
Chemical name :(bis[(E)-7-[4(-flurophenyl)-6-isopropyl-  
2[methyl(methylsulphonyl)amino]pyrimidin
-5-yl](3R,4S)-3,5-dihydroxyhept-6-enoic 
acid] calcium salt 
Characters 
Appearance              : An Off White to creamish white crystalline 
powder 
Solubility                                             : Sparingly soluble water and methanol and 
slightly Soluble in ethanol 
Loss on drying               : ≤ 5% 
Melting point                                            : 122
0
C 
Sulphated ash              : ≤0.1% 
Pharmacokinetics
61 
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 Absorption    :  Rosuvastatin calcium reaches the peak 
plasma concentration within 3 to 5 hours following the oral dosing. The 
absolute bioavailability is approximately 20%. 
 Protein binding   :   More than 88% bound to plasma protein, 
mostly albumin   
 Metabolism   : Rosuvastatin calcium is not extensively 
metabolized. About 10% is available as its metabolite most metabolites 
appearing in the urine 
 Half-life    : 19 hours 
 Excretion    : Following oral administration it is 
primarily excreted in the faeces (90%). About 28% excreted via urine and 72% 
by hepatic route. 
Mechanism of action 
 Rosuvastatin calcium is a competitive inhibitor of HMG-CoA reductase. HMG-
CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early 
rate-limiting step in cholesterol biosynthesis. Rosuvastatin acts primarily in the 
liver and results in the decrease in plasma LDL and VLDL.  
 Adverse reactions  
It is generally well tolerated. Side effects include myalgia, constipation, asthenia, 
abdominal pain and nausea. Other possible side effects include myotoxicity (myopathy, 
myositis and rhabdomyolysis) and hepatotoxicity 
Dosage     : Oral- 10 mg to 40 mg per day (film coated 
tablets) 
Contra indications    : hypersensitivity Patients with active liver 
disease,  
Administration    : Taken with or without food  
Therapeutic indications   : As hypolipidemic agent 
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Conventional tablets available in the market: 
Crestor® (AstraZeneca) 
Rosulip® (Cipla) 
Razel® (Glenmark) 
Novastat® (Lupin) 
Rosuvas® (Ranbaxy) 
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EXCIPIENTS PROFILE
62 
PHARMACEUTICAL   EXCIPIENTS: 
Excipients are substances other than the pharmacologically active drug or prodrugs, which 
are included in the manufacturing Process or contained in the pharmaceutical finished 
product or dosage Form. 
Excipients play a wide variety of functional role in pharmaceuticals dosage forms including, 
 Modifies the solubility and bioavailability of active pharmaceutical ingredients (APIs). 
 Increasing the stability of active ingredients the dosage forms. 
 Maintaining the pH and/or osmolarity of liquid formulations. 
 Helping active ingredients maintained preferred polymorphic Forms or conformation 
 Modulating immunogenic responses of active ingredients (e.g., adjuvants). 
 Acting as  
 
 Antioxidants 
 Emulsifying agents 
 Aerosol propellant 
 Tablet binders 
 Tablet disintegrant. 
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HYDROXY PROPYL METHYL CELLULOSE
62 
1. Non-proprietary Name: 
BP: Hypromellose, JP: Hypromellose PhEur: Hypromellose USP: Hypromellose  
2. Synonyms: 
  Benecel MHPC; E464; hydroxyl propyl methyl cellulose ;HPMC hypromellosum; 
methocel; methyl cellulose propylene glycol ether; methyl hydroxyl propyl cellulose; 
metolose ; MHPC; Pharmacoat; Tylophor; Tylose 
3. Chemical Name: 
      Cellulose hydroxyl propyl methyl ether  
4. Molecular weight:  
Molecular weight approximately 10000-1500000 
5. Functional category: 
Bio adhesive material, coating agent, controlled release agent, emulsifying agent, film 
forming agent, suspending agent, sustained release agent, tablet binder. 
6. Description: 
           Hypromellose is an odourless and tasteless, white or creamy – white fibrous or 
granular powder. 
7. Solubility : 
           Soluble in cold water, forming a viscous colloidal solution; practically insoluble in hot 
water, chloroform, ethanol (95%) and ether 
8. Applications: 
       HPMC is widely used in oral, ophthalmic, nasal and topical pharmaceutical 
formulations.it is used as tablet binder in film-coating and as a matrix for extended 
release tablet formulations .concentrations between 2-5% used as binder in either wet or 
dry granulation processes. High viscosity grades may be used to retard the release of 
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drugs from a matrix at levels of 10-80%w/w in tablets and capsules. Hypromellose is also 
used in liquid oral dosage forms as a suspending and/or thickening agent at 
concentrations ranging from 0.25-5.0% 
STARCH
62 
1. Non-proprietary Name: 
BP: Maize starch, potato starch, tapioca starch, rice starch JP: corn 
Starch, potato starch, rice starch, wheat starch pea starch, wheat starch USP NF: Cornstarch, 
potato starch, tapioca starch 
2.  Synonyms: 
Amido; amidon ;amilo ;amylum; C*PharmGel; Eurylon; fecule; Hylon;Maydisamylum; 
Melojel; meritena; oryzaeamylum; pearl; perfectamyl;Pisiamylum; solaniamylum. 
3. Chemical Name: 
          Starch 
4. Empirical Formula:  
        (C6H10O5)Where n=300-1000. 
5 .Functional category: 
         Tablet and capsule diluents, disintegrant, binder and thickening agent. 
6. Description: 
           Starch occurs as odorless and tasteless, white to off-white powder. 
7. Solubility: 
             Practically insoluble in cold water (96%) and in cold water. Starch becomes soluble 
in hot water at temperatures above the gelatinization temperature. Starch is partially soluble 
in dimethylsulfoxide and dimethylformamide.  
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8. Applications: 
             Starch is a versatile excipient used primarily in oral solid- dosage formulations 
were it is utilized as binder, diluents, and disintegrant. In tablet formulations freshly 
prepared starch paste is used at a concentration of (5-10%, depending on the starch type) 
as a binder. 
SODIUM STARCH GLYCOLATE
62 
1. Non-proprietary name: 
         BP: Sodium starch glycolate, phEur: sodium starch glycolate.  
2. Synonyms: 
       Carboxymethyl starch, sodium salt, carboxymethyl amylum natricum; Explosol, 
glycolys, primojel, tablo; viva star p. 
3. Chemical name: 
       Sodium carboxy methyl starch. 
4. Functional category: 
        Tablet and capsule disintegrant. 
5. Description: 
      Sodium starch glycolate is a white or almost white free- flowing hygroscopic powder. 
6. Solubility: 
               Practically insoluble in methylene chloride. It gives a translucent suspension in water. 
7. Applications: 
It is widely used in oral pharmaceuticals as a disintegrant in capsule and tablet 
formulations. It is commonly used in tablet prepared by direct compression or wet 
granulation process. The usual concentration employed in formulation is between 2% and 
8%, with the optimum concentration of about 4%.disintegration occurs by rapid uptake of 
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water and enormous swelling. Increasing the tablet compression pressure also appears to 
have no effect on disintegration time. 
MAGNESIUM STEARATE
62 
1. Non-proprietary names: 
     BP:Magnesium stearate, JP:  magnesium stearate, 
PhEur:magnesium stearate, USP-NF:Magnesium stearate. 
Synonyms: 
        Dibasic magnesium stearate, Magnesiudistearate; Magnesia stearas; magnesium 
octadecanoate; octadecanoicacid, magnesiumsalt; Synpro 90. 
2. Chemical name: 
Octa decanoic acid, Magnesium salt. 
3. Empirical formula: 
           C36H70MgO4 
5. Molecular weight: 
591.24 
6. Functional category: 
Tablet and capsule lubricant. 
8. Description: 
          Magnesium stearate is a very fine, light white, impalpable powder of low bulk density, 
having a faint odour of stearic acid and a characteristic taste. The powder is greasy to the 
touch and readily adheres to the skin. 
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9. Incompatibilities: 
Incompatible with strong acids, alkalis and iron salts. 
10. Applications: 
      It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0%w/w. It is hydrophobic and may retard the dissolution of a drug 
from solid dosage form. The lowest possible concentration is therefore used in such 
formulations. 
ETHYL CELLULOSE
62 
1.  Non-proprietary names: 
     BP: Ethyl cellulose, PhEur: Ethyl cellulose, USP-NF: Ethyl cellulose 
2.  Synonyms: 
                Aquacoat ECD; Aqualon; Ashacel; E462; Ethocel; Ethylcellosum; surelease. 
3. Chemical name: 
Cellulose ethyl ether. 
4. Empirical formula & Molecular weight: 
           Ethyl cellulose is partially ethoxylated. Ethyl cellulose with complete ethoxyl substitution 
(DS=3) is C12H23O6 (C12H22O5) n C12H23O5 where may vary to provide a wide variety of 
molecular weight. 
5. Functional category: 
Coating agent, flavoring agent; tablet binder; tablet filler viscosity increasing agent.  
6. Description: 
           Ethyl cellulose is a tasteless, free flowing, white to light tan – colored powder.  
7. Incompatibilities: 
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Incompatible with paraffin wax and microcrystalline wax. 
8. Applications: 
      The main use of ethyl cellulose in oral formulation as a hydrophobic coating agent for tablets 
and granules. Ethyl cellulose coatings are used to modify the release of a drug, to mask the 
unpleasant taste or to improve the stability of a formulation; modified release tablet formulation 
May also be produced   using ethyl cellulose as a matrix former. High viscosity grade are used in 
microencapsulation. It is used as a binder in dry or wet granulation process of tablets and 
thickening agent in creams, lotions and gels. 
XANTHUM GUM
62 
1. Non-proprietary names: 
     BP: Xanthan gum, PhEur: Xanthani gummi, USP-NF: Xanthan gum 
2. Synonyms: 
               Corn sugar gum; E415; Keltrol; polysaccharide B-1459, Rhodigel, Vansan NF, 
Xantural. 
3.  Chemical name: 
Xanthan gum 
4. Empirical formula and Molecular weight: 
           (C35H49O29)n. Xanthan gum as a high molecular weight polysaccharide gum. It contains D-
glucose and D-mannose as a dominant hexose units, along with D- glucuronic acid and is 
prepared as the sodium, potassium or calcium salt. 
5. Structural formula: 
           Each xanthan gum repeat units contains five sugar residues: two glucose, two mannose 
and one glucuronic acid. The polymer backbone consist of four b-D-glucose units linked the 1 
and 4 positions and is therefore identical in structure to cellulose  
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6. Functional category: 
Stabilizing agent; viscosity increasing agent; suspending agent.  
7. Description: 
           Xanthan gum occurs as a cream or whit colored odorless, free flowing, fine powder  
    
8.  Applications: 
      Xanthan gum is widely used in oral and topical formulation cosmetics and food as a 
stabilizing agent. It is also used as emulsifying agent and thickening agent.it is non- toxic, 
compatible with most other pharmaceutical ingredients and has good stability and viscosity 
properties over wide pH and temperature range.it is also used as a matrix former in sustained 
release tablets.it increases the retention time of the ophthalmic solutions in eye and as 
Bioadhesive polymer.  
9. Stability: 
  Xanthan gum is a stable material. Aqueous solutions are stable over a wide pH range 
(pH 3-12), the stability at pH 4- 10 and temperature at 10-60  is maximum. 
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MICROCRYSTALLINE CELLULOSE
62 
1. Non-proprietary name: 
BP: Microcrystalline cellulose USP-NF: Microcrystalline cellulose; 
NF: Microcrystalline cellulose. 
2. Synonyms: 
AvicelPH; Cellulosegel, Crystalline cellulose. 
3. Chemical Name: 
Cellulose  
4. Empirical Formula:  
(C6H10O5)n  where n = 220. 
5. Functional Category: 
Tablet and capsule diluents; Adsorbent; tablet disintegrant, suspending agent;                                     
6. Description: 
Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a white, 
odorless, tasteless, crystalline powder composed of porous particles. It is commercially available 
in different particle sizes and moisture grades that have different properties and applications. 
7. Solubility: 
Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, dilute 
acids, and most organic solvents. 
8. Incompatibilities: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
 
9. Applications: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent in oral 
tablet and capsule formulations where it is used in both wet-granulation and direct-compression 
processes. In addition to its use as binder/diluents, microcrystalline cellulose also has some 
lubricant and disintegrants properties that make it useful in tableting. 
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SODIUM BICARBONATE
62 
1. Non-proprietary name: 
BP: Sodium bicarbonate, JP: Sodium bicarbonate, PhEur: Natrii hydrogeno carbonas, 
USP: Sodium bicarbonate 
2. Synonyms: 
Baking soda; E500; Effer –soda; monosodium carbonate; Sal de vichy; Sodium acid 
carbonate; sodium hydrogen carbonate. 
3. Chemical Name: 
Carbonic acid monosodium salt  
4. Empirical Formula:  
NaHCO3 84.01 
5. Functional Category: 
Alkalizing and therapeutic agent.                                     
6. Description: 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with saline, 
slightly alkaline taste. The crystal structure is monoclinic prisms. 
7. Incompatibilities: 
Reacts with acids, acidic salts and alkaloid salts.  
8. Applications: 
Sodium bicarbonate is used as a source of CO2 in the formulation or technology 
effervescent tablets and granules. In effervescent tablet and granules, sodium bicarbonate is 
usually formulated with citric acid or tartaric acid; tablets prepared with sodium bicarbonate 
alone since the gastric fluid is sufficient to produce the effervescences; it is also used in tablet 
formulations to buffer the drug molecules that are weak acids, thereby increasing the rate of 
dissolution and reducing gastric irritation. Recently it is used as a gas generating agent in 
floating systems and alginate raft systems.  
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ISOPROPYL ALCOHOL
62 
1. Non-proprietary name: 
BP: Isopropylalcohol, PhEur: Isopropylalcohol, USP: Isopropyl alcohol. 
2. Synonyms: 
         Dimethyl carbinol, IPA, Isopropanol, petrohol, sec-propyl alcohol 
 
3. Chemical Name: 
Propan-2-ol. 
4. Empirical Formula: 
C3H8O 
5. Molecular Weight: 
        60.1 
6. Functional category: 
Disinfectant, solvent 
7. Description: 
         It is a clear, colourless, mobile, volatile, flammable liquid with a characteristic, 
spirituous odour resembling that of a mixture of ethanol and acetone, it has slightly bitter 
taste. 
8. Solubility: 
Miscible with benzene, chloroform, ethanol (95%), ether, glycerin and water. 
9. Incompatibilities: 
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Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid. 
POVIDONE
62
 
1. Nonproprietary name: 
                   Povidone 
2. Synonyms: 
                   E1201; kollidon; plasdone; poly[1-(2-oxo-1-pyrolidinyl) ethylene]; polyvidone; 
polyvinyl pyrrolidone; povidonum; PVP; povipharm; 1-vinyl-2-pyrolidone polymer 
3. Chemical name: 
                   1 -ethenyl-2-pyrollidone homopolymer. 
4. Empirical formula: 
                   (C6H9NO)n 
5. Molecular weight: 
                    2500-3,000,000 
6. Functional category: 
                    Disintegrant; dissolution enhancer; suspending agent; tablet binder. 
7. Description: 
                     Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidone with equal to or lower than 30 are manufactured by 
spray drying and occurs as spheres. Povidone K90 and higher k-values manufactured drum 
drying and occurs as plates  
8. Incompatibilities: 
                     Incompatible with inorganic salts, natural and synthetic resins. 
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9. Application: 
                     In tablets, Povidone solutions are used as binders in wet granulation processes. 
Povidone is also added to powder blends in the dry form and granulated in situ by the 
addition of water, alcohol or hydro alcoholic solutions. It is used as a solubilizer in oral and 
parenteral formulations.  
 Povidone is used as a coating agent. Povidone is additionally used as suspending; 
stabilizing and viscosity increasing agent in topical and oral suspensions and solutions. The 
solubility of poorly soluble drugs can be increased by mixing with povidone   
ERYTHROSIN
63 
1. Nonproprietary name: 
                   Erythrosine natrium  
2. Synonyms: 
                   Erythrosine B; Erythrosin B; Acid Red 51; C.I. 45430; FD & C Red No.3; E127; 
2',4',5',7'-Tetraiodo-3',6'-dihydroxy-spiro[3H-isobenzofuran-1,9'-xanthen]-3-one disodium salt; 
Tetraiodofluorescein Sodium Salt; Calcoid Erythrosine N; 2,4,5,7-Tetraiodo-3,6-
dihydroxyxanthene-9-spiro-1'-3H-isobenzofuran-3'-one disodium salt; 2',4',5',7'-
Tetraiodofluorescein, disodium salt; C.I.Food Red 14; Aizen Erythrosine; Tetraiodifluorescein, 
disodium salt; Spiro[isobenzofuran- 1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-2',4',5',7'-
tetraiodo-, disodium salt 
3. Chemical name: 
                   2-(6-Hydroxy-2, 4, 5, 7-tetraiodo-3-oxo-xanthen-9-yl) benzoic acid 
4. Empirical formula: 
                 C20H6I4Na2O5 
     5.  Molecular weight: 
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                    879.86 g/mol 
    6. Melting point: 
           303 °C 
    7.  Functional category: 
                    It is cherry-pink synthetic colorant  
  8.Description: 
                   Maroon color powder and hygroscopic 
  9.Application: 
Erythrosine B is an iodo derivative of fluorescin with distinctly bluish shade whereas eosin is 
a bromine derivatives of fluorescin. It is used in coloring cosmetics and food. It is used as a 
plasma stain for nerve cells and staining bacteria in soil. It is used as a phosphorescent triplet 
probe to detect rotational diffusion of membrane proteins 
STARCH PHOSPHATE
64
 
Solubility  of  starch  phosphate  was  tested  in  water,  aqueous buffers  of  pH  1.2,  4.5,  
and  7.4  and  organic  solvents  such  as alcohol, dichloromethane, chloroform, acetone and 
petroleum ether. 
1. pH  
The pH of 1% w/v slurry was measured. 
2. Melting Point 
Melting point was determined by using melting point apparatus. 
3. Viscosity 
Viscosity of 1% dispersion in water was measured using Ostwald Viscometer. 
4. Swelling Index 
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Starch phosphate (200 mg) was added to 10 ml of water and light liquid paraffin taken in 
two different graduated test tubes and mixed.  The dispersion in the tubes was allowed to 
stand for 12 h. The volumes of the sediment in the tubes were recorded.  The swelling 
index of the material was calculated as follows. 
Volume of sediment in water – Volume of sediment in light liquid paraffin   
S.I (%) =   × 100 
Volume of sediment in light liquid paraffin 
5. Test for gelling property 
The gelling property (gelatinization) of the starch and starch phosphate prepared was 
evaluated by heating a 7% w/v dispersion of each in water at 100°C for 30 min. 
6. Moisture absorption 
The hygroscopic nature of starch phosphate was evaluated by moisture absorption studies  
in  a  closed  desiccator  at  84% relative humidity and room temperature. 
7. Particle size 
Particle size analysis was done by sieving using standard sieves. 
8. Density 
Density (g/cc) was determined by liquid displacement method using benzene as liquid. 
9. Bulk density 
Bulk density (g/cc) was determined by three tap method in a graduated cylinder. 
10. Angle of repose 
Angle of repose was measured by fixed funnel method. 
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11. Compressibility index  
Compressibility index (CI) was determined by measuring the initial volume (Vo) and 
final volume (V) after hundred. 
  
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
Table 2:   List of materials and their applications in formulation 
S.No Name of material Manufacturer / supplier Use in formulation 
1 Propranolol hydrochloride Sri Sai supreme chemicals  Active ingredient 
2 Rosuvastatin calcium  
 
Biocon Pharma Ltd Active ingredient 
3 HPMC K4M 
 
Pharma French Ltd Hydrophilic polymer 
4 HPMC K100M 
 
Pharma French Ltd Hydrophilic polymer 
5 Xanthan gum 
 
Pharma French Ltd Hydrophilic polymer 
6 Ethyl cellulose 
 
Pharma French Ltd Non swellable polymer 
7 Micro crystalline 
cellulose 
Pharma French Ltd Diluent  
8 Starch  
 
Pharma French Ltd Diluent 
9 Sodium starch glycolate 
 
Pharma French Ltd Super disintegrant 
10 Sodium bicarbonate 
 
Indian research products Gas generating agent 
11 PVP K30 
 
Kniss laboretories Binding agent 
12 Magnesium stearate 
 
Kniss laboretories Lubricant  
13 Isopropyl alcohol 
 
Microfine chemicals Solvent 
14 Erythrosine Kwality pharmaceuticals  Colorant  
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Table 3: List of equipments used 
 
S.NO Equipment’s / instruments Manufacturer /supplier 
1 Electronic weighing balance 
 
Asha scientific company, 
Mumbai 
2 Hot air oven 
 
MC Dalal, Chennai 
3 10 Station compression machine 
 
Rimek, India 
4 Vernier caliper 
 
Mitutoyo, Japan 
5 Monsanto hardness tester 
 
Erweka, Mumbai 
6 Friabilator 
 
Electrolab, India 
7 P
H 
meter 
 
MC Dalal, Chennai 
8 Disintegration apparatus 
 
Electrolab, India 
9 Dissolution tester 
 
Veego, India 
10 UV-visible spectrophotometer 
 
Shimadzu, Japan 
11 Fourier transform infra-red spectrophotometer 
 
Nicolet, India 
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PREFORMULATION STUDIES 
The Preformulation studies are conducted to establish the physiochemical 
characteristics of the drug and its compatibility with the various excipients. The 
Preformulation studies are necessary to formulate drug into stable, safe and effective 
dosage form. 
Drug-excipient compatibility study
 
The drug and excipients selected for the formulation are evaluated for physical and 
chemical compatibility studies. 
Physical compatibility study
67
: 
The physical compatibility studies are conducted to provide valuable information to the 
formulator in selecting the appropriate excipients for the formulation. It was done by 
mixing the drugs and excipients and kept at room temperature and at 40°C and 75%RH. 
Any color change of the physical mixture was observed visually. 
Chemical compatibility study
67
: 
Pure drugs, polymers, excipients, drug-excipient mixture was subjected to FTIR to 
investigate the drug-excipient interactions. The IR spectra of test samples are obtained 
using potassium bromide pellet method. 
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Calibration curve : 
1. Calibration curve of Propranolol Hydrochloride65 
100mg of Propranolol was dissolved in 10ml of 0.1 N HCl and made upto 
100ml using 0.1N HCL in standard flask. From the above solution 10ml was 
taken and made upto 100ml using 0.1N HCL. From the above solution 2ml,4ml, 
6ml,8ml and 10ml were taken and upto 100ml using 0.1N HCL. The absorbance 
of resulting solutions is measured at 290nm using UV spectrophotometer. 
Calibration curve was plotted. 
 
2. Calibration curve of Rosuvastatin calcium66 
50 mg of Rosuvastatin calcium was dissolved in 5ml of Methanol and 
made upto 50ml using 0.1N HCL in a 50ml standard flask. From the above 
solution 5ml was taken and made upto 50ml using 0.1N HCL. From the above 
solution 2ml,4ml, 6ml,8ml and 10ml were taken and made upto 100ml using 0.1N 
HCL. The absorbance of resulting solutions is measured at 240nm using UV 
spectrophotometer. The Calibration curve was then plotted. 
Precompression studies of drugs and blends 
The flow property measurements include bulk density, tapped density, angle of 
repose, compressibility index and Hausner’s ratio. The flow property measurements of 
drugs and blends are determined to select the type of granulation to be carried out in the 
formulation. 
I. Bulk density67 
Bulk density is the ratio of weight of powder to bulk volume. A sample of 10g of 
powder has been carefully introduced into measuring cylinder with the aid of 
funnel and volume occupied by the powder was noted. Bulk density is expressed 
in g/ml. 
                                            M 
                  Bulk density=   
                                            Vb 
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Where, 
             M = weight of sample in grams 
             Vb=bulk volume 
 
II. Tapped density67 
Tapped density is the ratio of weight of powder to tapped volume of powder. The 
10g of powder was introduced into the measuring cylinder with the aid of funnel 
and tapped for 500 times on a hard wooden surface at 2 seconds interval and the 
volume obtained was noted. Tapped density is expressed in g/ml 
 
                                             M 
               Tapped density=      
                                             Vt 
Where, 
            M = weight of sample in grams 
            Vt= tapped volume 
III. Angle of repose67 
Angle of repose measures the frictional force involved in the powder. It is defined 
as the maximum angle possible between the surface of a pile of powder and the 
horizontal plane. It is determined by fixed funnel method. The powder mixtures 
allowed to flow through the funnel method to a stand at define height. The angle 
of repose is then calculated by the formula mentioned below. 
                         θ= tan-1(h/r) 
Where, 
           θ= angle of repose in degrees 
           h= height of the pile of powder in cm 
           r= radius of pile of powder in cm 
Table 4: Angle of repose 
Flow property Angle of repose (in 
degrees) 
Compressibility index 
(%) 
Hausner’s ratio 
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Excellent  25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair  36-40 16-20 1.19-1.25 
Passable  41-45 21-25 1.26-1.34 
Poor  46-55 
 
26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >65 >38 >1.60 
 
I. Compressibility index or Carr’s index68 
Compressibility index is the measure of flow property of a powder. It is measured 
for determining the relative importance of interparticulate interactions. It is 
expressed in percentage and calculated by formula mentioned below. 
                                      Tapped density-bulk density 
       Compressibility index=            x 100                                                                                                                                              
                                                Tapped density 
II. Hausner’s ratio68 
Hausner’s ratio is the measure of propensity of powder to be compressed and also 
interparticulate interactions. Hausner’s ratio is calculated by formula mentioned 
below. 
                                         Tapped density 
          Hausner’s ratio=    
                                           Bulk density                                 
FORMULATION DEVELOPMENT
66 
Formulation of Rosuvastatin Calcium- Starch Phosphate Solid Dispersion 
Preparation of Starch Phosphate 
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Starch phosphate was prepared based on the method of Choi et al with some 
modifications.  Potato  starch  (100  g)  and di-sodium  hydrogen  orthophosphate  
anhydrous  (30  g)  were suspended in 100 ml of water and continuously stirred for 20 
min.  This  starch  slurry  was  then  filtered  and  the  wet  starch mixture  was  
conditioned  for  12  h  at  room  temperature (28
0
C). To enhance phosphorylation, this 
mixture was heated in a forced air oven at 130°C for 3 h.The product obtained was 
ground and sized. 
Preparation of Solid Dispersions of Rosuvastatin calcium 
Phosphate Solid  dispersions  of  Rosuvastatin calcium and  starch  phosphate  
were prepared  in  1:1  (SD-1),  1:2  (SD-2),  1:3  (SD-3) and 1:4 (SD-4) ratios of drug: 
carrier by solvent evaporation method.  Rosuvastatin calcium (1  g)  was  dissolved  in  
Methanol  (10  ml)  in  a  dry  mortar  to  get  a  clear  solution.  Starch phosphate (1 g) 
was then added and mixed.  The thick slurry was  triturated  for  15  min  for  complete  
evaporation  of Methanol  and  then  dried  at  55
o
C until  dry. The dried mass was 
pulverized and sieved through mesh no.100. 
Table 5: Formulation of Rosuvastatin solid dispersion 
S.No Ingredients SD-1 SD-2 SD-3 SD-4 
1 Rosuvastatin calcium 10 10 10 10 
2 Starch Phosphate 10 20 30 40 
 
FOR ROSUVASTATIN SOLID DISPERSION: 
Fourier transforms infrared (FTIR) spectroscopy   
FTIR spectra were recorded on samples prepared in potassium bromide  (KBr) 
disks. Samples were prepared in KBr disks in a hydrostatic press at 6-8 tons pressure. 
The scanning range was 500 to 4000 cm
 -1
 
Estimation of Rosuvastatin calcium  
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An UV  spectrophotometric  method  based  on  the measurement  of  absorbance  
at  240 nm in 0.1N HCl was used for estimation  of  Rosuvastatin calcium. When  the  
standard  drug  solution  was  assayed repeatedly (n=6), the relative error (accuracy) and 
coefficient of  variation  (precision)  were  found  to  be  0.60%  and  1.0% respectively.  
No interference from excipients used was observed. 
Invitro dissolution study  
The Invitro dissolution study was carried out using a USP apparatus II in 900 ml 
of 0.1 N HCl for one hour for accurately weighed amount of the formulations (containing 
approx.10 mg of Rosuvastatin calcium). The  rotational  speed  of  the paddle  was  set  at  
50  rpm  at  37  ±  0.5ºC.   (10ml of solution were withdrawn at predetermined time 
intervals of every 10 minutes  for 1h; sink conditions  were  maintained. The samples 
were analyzed for drug content using a double beam UV spectrophotometer at 240 nm 
Formulation of Rosuvastatin Calcium Immediate tablets:  
The immediate release tablets each containing 10 mg of Rosuvastatin calcium 
were prepared  by  wet  granulation  method  employing  Rosuvastatin calcium alone  and  
its  solid  dispersions  in  starch phosphate. Sodium starch glycolate was used as a super 
disintegrant. 
Starch   was  used  as  diluent  to  adjust  the  weight of  the  tablet  to  150  mg. 
PVPK-30, Magnesium  stearate  (2%)  were  incorporated  respectively as binder and 
lubricants. The tablet granules were prepared by wet granulation method and then 
compressed into tablets on a    REMEK 10-station rotary  tablet  punching  machine using 
8 mm flat punch 
Table 6: Formulation of immediate release solid dispersion tablet of 
rosuvastatin calcium 
S.NO INGREDIENTS R-I R-II R-III 
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Average weight of each tablet = 150mg 
The immediate release tablet of Rosuvastatin calcium was formulated and optimized. The 
optimized formulation was used to formulate bilayer floating tablets. 
 
 
 
 
 
 
 
 
 
 
 
1 Rosuvastatin calcium 10 - - 
2 Rosuvastatin solid dispersion - 40 50 
3 Starch 129 99 89 
4 PVP K30 3 3 3 
5 Sodium starch glycolate 6 6 6 
6 Magnesium stearate 2 2 2 
7 Isopropyl alcohol Q.S Q.S Q.S 
Rosuvastatin calcium 
Starch 
Starch phosphate 
PVP K30 
SSG 
Magnesium stearate 
Isopropyl alcohol 
 
Dispensing Sifting and blending of 
ingredients 
Precompression study 
of powder blends 
Wet granulated with 
PVP K30 in IPA 
Post compression 
studies 
Materials and methods 
 
Department of pharmaceutics, Madras Medical College. Page 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation of Sustained Release Propranolol Hydrochloride floating tablets
67 
The sustained release granules of Propranolol Hydrochloride were prepared by 
wet granulation technique. Different polymers such as HPMC K4M, HPMC K100, Ethyl 
cellulose and xanthan gum were used. The concentrations of HPMC K4M and HPMC 
K100 were taken as variables. The granules were compressed by 10 station tablet 
compression machine using 8mm punches. 
Table 7: Formulation of sustained release floating layer of Propranolol 
Hydrochloride  
 
S.No Ingredients 
P-I P-II P-III P-IV P-V P-VI P-VII 
1 
Propranolol HCl 80 80 80 80 80 80 80 
Dried and mixed with 
SSG 
Lubricated with 
magnesium stearate 
and compression 
Rosuvastatin 
calcium IR SD 
tablets 
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2 HPMC K 100 40 60 80 100 0 0 0 
3 HPMC K4M 0 0 0 0 40 60 80 
4 Xanthum gum 20 20 20 20 20 20 20 
5 Microcrystalline 
cellulose 60.5 40.5 20.5 0.5 60.5 40.5 20.5 
6 Ethyl cellulose 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
7 Sodium bicarbonate 20 20 20 20 20 20 20 
8 PVP K 30 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
9 IPA QS QS QS QS QS QS QS 
10 
Magnesium stearate 4.5 4.5 4.5 4.5 4.5 4.5 4.5 
 
Total weight of the tablet = 250 mg 
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Propranolol hydrochloride 
HPMC K100 
HPMC K4M 
Microcrystalline cellulose 
Ethyl cellulose 
Sodium bicarbonate 
Xanthan gum 
PVP K30 
IPA 
Magnesium stearate 
Dispensing  Shifting  
Mixed with ethyl 
cellulose 
Blended with HPMC 
K100 and Xanthan 
gum or HPMC K4M 
and Xanthan gum 
Precompression study 
Wet granulated with 
PVP K30 in IPA 
Drying and lubricated with 
magnesium stearate 
Compression  
Propranolol hydrochloride SR Floating tablets 
Post compression studies 
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POST COMPRESSION STUDIES
 
1. PHYSICAL PARAMETERS  
General appearance: 
 The general appearance of the tablets from each formulation batch was observed. 
The general appearance parameters are shape, color, presence or absence of odor and 
taste were evaluated. 
Uniformity of weight
58
: 
  Twenty tablets were selected at a random and weighed individually. The average 
weight was also measured. The percentage deviation of tablets was calculated and 
compared with standard specifications. 
Thickness and diameter
70, 71
: 
 The thickness and diameter was measured to determine the uniformity of size and 
shape. Thickness and diameter of the tablets were measured using Vernier caliper. 
Hardness
71
: 
 Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as tablet crushing strength. Hardness of the prepared 
formulations was determined using Monsanto hardness tester. It was expressed in 
kg/cm
2
 
Friability
71
: 
 Friability of the prepared formulations was determined by using Rochelle 
Friabilator. Pre-weighed sample of tablets was placed in the friability tester, which 
was then operated for 100 revolutions, tablets were dedusted and reweighed. The 
friability of the tablets was calculated using the formula mentioned below  
          Friability =  Initial weight of the tablets – Final weight of the tablet 
    Final weight of the tablets  
2. DRUG CONTENT 
FOR IR TABLETS CONTAINING ROSUVASTATIN CALCIUM
48
  
 Twenty tablets were selected randomly and ground. The powder equivalent of 10 
mg Rosuvastatin calcium was weighed, mixed with methanol and made upto 10 ml. It 
was kept overnight, filtered and diluted to 50 ml with 0.1N HCl acid. The standard 
solution was also prepared in the same manner. The absorbance of the standard and 
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sample solution was measured at 240 nm. The amount of rosuvastatin calcium was 
determined. 
BILAYER FLOATING TABLETS CONTAINING PROPRANOLOL 
HYDROCHLORIDE AND ROSUVASTATIN CALCIUM BY SIMULTANEOUS 
ESTIMATION METHOD
72
 
 
Simultaneous estimation of propranolol hydrochloride and rosuvastatin calcium was 
carried out using UV spectrophotometer. 
PROCEDURE: 
The following equations were used to determine the contents. 
  CX =          A2ay1 - A1ay2 
                                                                ax2 ay1- ax1 ay2 
                       CY =       A1aX2 – A2aX1 
                                                              ax2 ay1- ax1 ay2 
 
Where              ax1 and ax2= the absorptivity of drug X at λ1 and λ2   respectively  
                         ay1 and ay2= the absorptivity of drug Y at λ1 and λ2  respecively 
   A1 and A2 = the absorbance of sample at λ1 and λ2 respectively 
The ratios should lie outside the range of 0.1-2.0 for the precise determination of 
X and Y drugs respectively. This criteria is satisfied only when the λ max of the two 
components is reasonably dissimilar and the two components should not interact 
chemically. 
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Preparation of standard stock solution of Propranolol Hydrochloride: 
 Propranolol hydrochloride equivalent to 80 mg of propranolol was accurately 
weighed; 90 ml of 0.1N HCl was added and sonicated to dissolve. The volume was made 
upto the 100 ml with 0.1N HCl.  
 
Preparation of standard stock solution of Rosuvastatin Calcium: 
 Rosuvastatin calcium equivalent to 10 mg of Rosuvastatin was accurately 
weighed; 10 ml of methanol was added and further diluted to 50 ml with 0.1N HCl. 
Preparation of Mixed standard solution of Propranolol Hydrochloride and 
Rosuvastatin calcium  
 2ml each of the stock solutions of propranolol hydrochloride and rosuvastatin 
calcium were mixed and the volume was made upto 100ml with 0.1N HCl. 
Preparation of sample solution  
 Twenty tablets were accurately weighed and the average weight was calculated. 
The tablets were then ground to a fine powder. The powder equivalent to the average 
weight of the tablets was mixed with 0.1N HCl and made upto100 ml. the solution was 
kept overnight and filtered. 10 ml of the above solution was diluted to 100ml with 0.1N 
HCl. The absorbance of the solution was recorded at 240 nm and 290 nm. The amount of 
propranolol and rosuvastatin were determined           
3. In vitro disintegration studies for IR tablets58: 
One tablet each was placed in each of the six tubes of the basket. The assembly 
was suspended in water maintained at a temperature of 37
0
c ± 0.2
0
c and the apparatus 
was operated. The time taken to disintegrate the tablets completely was noted. 
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4. In vitro floating studies for BF tablets39: 
  Floating characteristics of the prepared formulations were determined using USP 
paddle apparatus at a speed of 50 rpm in 900ml of 0.1N HCl solution (pH=1.2) at 
37±0.2
0
c for 12 hours. The time between the introduction of tablet and its buoyancy on 
the simulated gastric fluid (floating lag time) and the time during which the dosage form 
remain buoyant (floating duration) were measured. Also, the matrix integrity of the 
tablets during the study was visually monitored. 
 
5. Invitro dissolution studies: 
For IR tablets
40
: 
The invitro dissolution study of Rosuvastatin calcium was carried out using USP 
Type II (Paddle) dissolution apparatus under sink condition. The dissolution medium was 
900 ml of a 0.1N HCl solution (pH=1.2), at 37
0
c±0.2
0
c at speed was 50 rpm. The in vitro 
release studies were carried out for 30 min by taking sample at every 5 minutes intervals. 
The absorbance of the solution was recorded at 240 nm using UV spectrophotometer. 
For bilayer floating tablets
73
:  
The invitro dissolution study of Propranolol hydrochloride and Rosuvastatin 
calcium bilayer floating tablets were determined using USP Type II (Paddle) dissolution 
apparatus under sink condition. The dissolution medium was 900 ml of a 0.1N HCl 
solution (pH=1.2), at  37
0
C±0.2
0
C at speed was 50 rpm. 10ml of the solution was 
collected from the dissolution medium at 10, 20, 30 min and at 1,2,3,4,5,6,7,8,9,10,11,12 
hour and were replaced with fresh dissolution medium. The solutions were filtered 
through whatmann filter paper no. 41. The absorbance of the solution was recorded at 
240nm and 290 nm using UV spectrophotometer. 
6. Swelling studies of bilayer floating tablets39: 
The extent of swelling was measured in terms of percentage weight gain by tablets. 
The swelling behavior of the optimized formulation was studied. Swelling index of the 
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optimized formulation was determined in 900 ml of 0.1N HCl solution (pH=1.2), at 37
0
-
C±0.5
0
C. At the end of 1,2,3,4,5,6,7,8,9,10,11 and 12 hours. Tablets were withdrawn and 
the excess of fluid was removed with a tissue paper, the tablets were weighed and the 
percentage weight gain by the tablet was calculated using the formula. 
   SI= Mt-M0  × 100 
       M0 
         Where, SI= Swelling index 
    Mt= Weight of tablet at time t and             
M0= Weight of tablet at time 0 
7. Evaluation of invitro release kinetics74: 
 To study the invitro release kinetics of the optimized BFT, data obtained from 
dissolution study were plotted in various kinetics models. 
1. Zero order equation :  
The zero order release can be obtained by plotting cumulative % percentage drug 
released vs. time in hours. It is ideal for the formulation to have release profile of zero 
order to achieve pharmacological prolonged action.  
   C=K0t 
   Where K0= Zero order constant  
         T= Time in hours  
2. First order equation: 
A graph was plotted with log % cumulative drug remaining Vs time in hours. 
    Log   C= log C0- Kt/2.303 
   Where C0= Initial concentration of drug  
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    K= First order   
      T= Time in hours 
3. Higuchi kinetics: 
A graph was plotted with % cumulative drug released vs. square root of time  
    Q = Kt 
½ 
  Where K= constant reflecting design variable system (differential rate 
constant)    t= Time in hours  
4. Hixon and Crowell erosion equation: 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixon and Crowell rate equation. A graph was 
plotted with cube root of % drug remaining vs. time in hours. 
    Q0
1/3
 – Qt1/3 = KHCXt  
   Where Qt= amount of drug released in time t. 
   Q0= Initial Amount of drug 
 KHC= Rate constant for Hixon Crowell equation. 
5. Korsmeyer-Peppas equation: 
To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released vs. log time   
    Mt/Mα =Kt
n 
Where    Mt/Mα = fraction of drug released at time t 
   t= release time  
K= Kinetics constant (incorporating structural and geometric 
characteristics of preparation) 
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N= Diffusional exponent indicative of mechanism of drug release 
If slope (n) values is 0.5 or less, the release mechanism is fickian diffusion and if 
0 < n < 1 it follows non fickian model (anomalous model). The drug release follows zero 
order drug release and non fickian case – II transport if the value is 1. For the values of n 
higher than 1, the mechanism of drug released is regarded as non- fickian super case II 
transport. The model is used to analyze the drug release of pharmaceutical polymeric 
dosage forms when the release mechanism is not known or more than one type of release 
is involved. 
6. Stability study69: 
Stability study of optimized bilayer floating tablets was carried out according to 
ICH guidelines. All tablets were packed in blister and kept in humidity chamber at 40±2
0
-
C and 75± 5% RH for 3 months. Samples were withdrawn at monthly intervals and 
analyzed for drug content, floating characteristics, hardness and in vitro dissolution. 
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RESULT AND DISCUSSION 
The present investigation was to formulate bilayer floating tablets for immediate release of 
rosuvastatin calcium and sustained release of propranolol hydrochloride for Hypertension with 
Hyperlipidemia. 
PREFORMULATION STUDIES: 
DRUG-EXCIPIENT COMPATIBILITY STUDY: 
The drug-excipient compatibility study was conducted to reveal the excipient compatibility 
with the drug. 
Table 8: Physical compatibility study of Drug and Excipients 
S.No  
Drug + Excipient  
Description and Condition 
Initial Room temperature  
and 40
0
C/ 75% 
RH in days 
10
th
  20
th
  30
th
  
1 PH White, almost white crystalline powder  NC NC NC 
2 RC White, almost white crystalline powder, 
Slightly Hygroscopic 
NC NC NC 
3 PH+RC White, almost white crystalline powder NC NC NC 
4 HPMC K4M White or creamy white crystalline powder NC NC NC 
5 HPMC K 100 White or creamy white crystalline powder NC NC NC 
6 Xanthan gum Creamy white Free flowing fine powder NC NC NC 
7 EC Free flowing white colored powder NC NC NC 
8 MCC White, crystalline powder NC NC NC 
9 PVPK30 White or Creamy white colored 
Hygroscopic powder  
NC NC NC 
10 Sodium bicarbonate White, crystalline powder NC NC NC 
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NC- No Change 
The physical compatibility study was performed visually. The study implies that the drug and 
excipients were physically compatible with each other as there was no change of physical 
description. The excipients which were compatible with the drugs were selected for formulation.   
 
11  Starch  White or off white  crystalline powder NC NC NC 
12 Starch Phosphate White or off white  crystalline powder NC NC NC 
13 Magnesium Stearate White or off white  crystalline powder NC NC NC 
14 Erythrosine Cherry pink color powder NC NC NC 
15 PH+HPMC K4M White, creamy white crystalline powder NC NC NC 
16 PH + HPMCK100 White, creamy white crystalline powder NC NC NC 
17 PH + Xanthan gum White, creamy white crystalline powder NC NC NC 
18 PH + EC White, almost white crystalline powder NC NC NC 
19 PH + MCC White, almost white crystalline powder NC NC NC 
20 PH + PVPK30 White, almost white crystalline powder NC NC NC 
21 PH + Sodium 
bicarbonate 
White, almost white crystalline powder NC NC NC 
22 PH + Magnesium 
stearate 
White, almost white crystalline powder NC NC NC 
23 RC + STARCH White, crystalline powder NC NC NC 
24 RC + STARCH 
PHOSPHATE 
White, crystalline powder NC NC NC 
25 RC +  Magnesium 
stearate 
White, crystalline powder NC NC NC 
26 RC + PVPK30 White, crystalline powder NC NC NC 
27 RC + White, crystalline powder NC NC NC 
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Chemical compatibility study  
The possible interaction between the drug and the excipients used in the formulation was 
studied by FTIR spectroscopy. The results are given in figures and tables 
FTIR SPECTROSCOPY OF DRUGS 
Fig 13: FTIR of Rosuvastatin Calcium 
 
 
Table 9: IR Spectral interpretation of Rosuvastatin Calcium 
Wave number (cm
-1
) Interpretation 
3363.61 Aromatic N-H stretching 
1550.85 C=O stretching 
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Fig 14: FTIR of Propranolol Hydrochloride 
 
 
 
Table 10: IR Spectral interpretation of Propranolol hydrochloride 
Wave number (cm
-1
) Interpretation 
3278.71 Secondary  amine –NH  stretching 
2962 C–H stretching 
1581.56 Aryl  C ¼ C stretching 
1265 Aryl O–CH2 asymmetric stretching 
  1026 Aryl O–CH2 symmetric stretching 
794   Peak due to alpha-substituted naphthalene 
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Fig 15: FTIR Spectroscopy of Rosuvastatin Calcium with Starch Phosphate 
 
 
 
Table 11: IR Spectral interpretation of Rosuvastatin Calcium in the form of Starch Phosphate 
Solid Dispersion 
Wave number (cm
-1
) Interpretation 
3363.61 Aromatic N-H stretching 
1550.85 C=O stretching 
 
The results of IR spectra of active ingredient and Excipient also revealed that there was no 
considerable change observed in bands of Rosuvastatin calcium. This shows the absence of any interaction 
between the drug and Starch phosphate. 
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Fig 16: FTIR Spectroscopy of Rosuvastatin Calcium with Polyvinyl pyrrolidone (PVP) 
 
 
 
Table 12: IR Spectral interpretation of Rosuvastatin Calcium with Polyvinyl pyrrolidone (PVP) 
Wave number (cm
-1
) Interpretation 
3363.61 Aromatic N-H stretching 
1550.85 C=O stretching 
 
The results of IR spectra of active ingredient and Excipient also revealed that there was no 
considerable change observed in bands of Rosuvastatin calcium. This shows the absence of any 
interaction between the drug and PVP K30. 
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Fig 17: FTIR Spectroscopy of Rosuvastatin Calcium with Sodium Starch Glycolate (SSG) 
 
 
 
 
Table 13: IR Spectral Interpretation of Rosuvastatin Calcium with Sodium Starch Glycolate (SSG) 
 
Wave number (cm
-1
) Interpretation 
3363.61 Aromatic N-H stretching 
1550.85 C=O stretching 
 
The results of IR spectra of active ingredient and Excipients also revealed that there was no 
considerable change observed in bands of Rosuvastatin calcium. This shows the absence of any 
interaction between the drug and SSG 
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PROPRANOLOL HYDROCHLORIDE FLOATING LAYER  
FTIR SPECTROSCOPY OF DRUG AND EXCIPIENTS 
Fig 18: FTIR of Propranolol with Ethyl Cellulose 
 
 
 
 
 
 
 
 
Table 14: IR Spectral interpretation of Propranolol with Ethyl Cellulose 
Wave number (cm
-1
) Interpretation 
3278.75 Secondary  amine –NH  stretching 
2923 C–H stretching 
1581.56 Aryl  C ¼ C stretching 
1265 Aryl O–CH2 asymmetric stretching 
  1026 Aryl O–CH2 symmetric stretching 
794   Peak due to alpha-substituted naphthalene 
 
The spectra indicated that there was no drug – excipient interaction as the peaks of the drug 
and the other excipient were seen in the drug excipient mixture. The study implies that the active 
ingredients and the excipient are chemically compatible with each other as there was no change in 
the IR spectral peaks. 
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Fig 19: FTIR of Propranolol with Xanthan Gum 
 
 
 
Table 15: IR Spectral interpretation of Propranolol with Xanthan Gum 
Wave number (cm
-1
) Interpretation 
3286.46 Secondary  amine –NH  stretching 
2923 C–H stretching 
1589.56 Aryl  C ¼ C stretching 
1265 Aryl O–CH2 asymmetric stretching 
  1026 Aryl O–CH2 symmetric stretching 
794   Peak due to alpha-substituted naphthalene 
 
The spectra indicated that there was no drug – excipient interaction as the peaks of the drug and the 
other excipients were seen in the drug excipient mixture. The study implies that the active 
ingredients and the excipient are chemically compatible with each other as there was no change in 
the IR spectral peaks 
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Fig 20: FTIR of Propranolol with Micro Crystalline Cellulose 
 
 
 
 
 
 
 
 
Table 16: IR Spectral Interpretation of Propranolol with Micro Crystalline Cellulose 
Wave number (cm
-1
) Interpretation 
3286.46 Secondary  amine –NH  stretching 
2923 C–H stretching 
1589.56 Aryl  C ¼ C stretching 
1265 Aryl O–CH2 asymmetric stretching 
  1026 Aryl O–CH2 symmetric stretching 
794   Peak due to alpha-substituted naphthalene 
 
The spectra indicated that there was no drug – excipient interaction as the peaks of the drug and the 
other excipients were seen in the drug excipient mixture. The study implies that the active 
ingredients and the excipient are chemically compatible with each other as there was no change in 
the IR spectral peaks. 
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Fig 21: FTIR of Propranolol Hydrochloride with HPMC K4M 
 
 
Table 17: IR Spectral Interpretation of Propranolol Hydrochloride with HPMC K4M 
Wave number (cm
-1
) Interpretation 
3286.46 Secondary  amine –NH  stretching 
2923 C–H stretching 
1589.56 Aryl  C ¼ C stretching 
1265 Aryl O–CH2 asymmetric stretching 
  1026 Aryl O–CH2 symmetric stretching 
794   Peak due to alpha-substituted naphthalene 
 
The spectra indicated that there was no drug – excipient interaction as the peaks of the drug 
and the other excipients were seen in the drug excipient mixture. The study implies that the active 
ingredients and the excipient are chemically compatible with each other as there was no change in 
the IR spectral peaks. 
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Fig 22: FTIR of Propranolol Hydrochloride with HPMC K100 
 
 
Table 18: IR Spectral Interpretation of Propranolol Hydrochloride with HPMC K100 
Wave number (cm
-1
) Interpretation 
3286.46 Secondary  amine –NH  stretching 
2923 C–H stretching 
1589.56 Aryl  C ¼ C stretching 
1265 Aryl O–CH2 asymmetric stretching 
  1026 Aryl O–CH2 symmetric stretching 
794   Peak due to alpha-substituted naphthalene 
 
The spectra indicated that there was no drug – excipient interaction as the peaks of the drug 
and the other excipients were seen in the drug excipient mixture. The study implies that the active 
ingredients and the excipient are chemically compatible with each other as there was no change in 
the IR spectral peaks. 
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CALIBRATION CURVE: 
The data for calibration curve of rosuvastatin calcium is given in table 19. 
Table 19: Data of calibration curve of Rosuvastatin calcium in 0.1 N HCl. 
Concentration 
(µg/ml) 
Absorbance 
at λ290nm 
0 0 
2 0.072 
4 0.142 
6 0.214 
8 0.282 
10 0.345 
 
Fig 23: Calibration curve of Rosuvastatin calcium 
 
 
 
 
 
 
 
 
 
It was found that the solutions of rosuvastatin calcium in 0.1 N HCl show linearity 
(R
2
=0.9993) and obey beer Lambert’s Law. 
 
y = 0.0347x + 0.0025 
R² = 0.9995 
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Calibration curve: 
The data for calibration curve of propranolol hydrochloride is given in table 20. 
Table 20: Data of calibration curve of Propranolol Hydrochloride in 0.1 N HCl. 
Concentration 
(µg/ml) 
Absorbance 
at λ290nm 
0 0 
2 0.040 
4 0.089 
6 0.127 
8 0.173 
10 0.214 
 
Fig 24: Calibration curve of Propranolol hydrochloride 
 
 
 
 
 
 
 
 
 
It was found that the solutions of propranolol hydrochloride in 0.1 N HCl show linearity 
(R
2
=0.9993) in absorbance at concentrations of 2-10 µg/ml and obey beer Lambert’s Law. 
 
y = 0.0215x - 0.0005 
R² = 0.9993 
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FOR ROSUVASTATIN CALCIUM SOLID DISPERSION: 
Fig 25: Fourier transforms infrared (FTIR) spectroscopy: 
 
 
 
Determination of drug content:  
The drug content of the solid dispersion of rosuvastatin calcium is given in the table 21 
Table 21: Drug content of Rosuvastatin solid dispersion 
Formulation  % Drug 
content*   
SD-1 99.55±0.180 
SD-2 99.05±0.207 
SD-3 97.49±0.456 
SD-4 96.98±0.342 
*Mean ±S.D (n=6) 
The drug content of solid dispersion was found to be within the Pharmacopoeial limits
58
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Invitro dissolution study:  
In vitro dissolution study of solid dispersion of rosuvastatin calcium is given in the table 22. 
Table 22: In Vitro Dissolution study of solid dispersion of Rosuvastatin calcium 
Time in 
minutes 
Cumulative % drug release * 
SD-1 SD-2 SD-3 SD-4 
10 31.688±0.736 53.644±0.542 70.740±0.447 72.890±0.232 
20 46.576±0.683 71.382±0.346 84.667±0.242 87.345±0.222 
30 59.675±0.534 85.290±0.463 97.112±0.473 99.780±0.443 
40 69.987±.323 95.106±0.574 101.05±0.453 101.414±0.564 
50 89.565±.314 96.689±0.749   
60 99.678±0.213 100.98±0.456   
 
Solid dispersion SD-3 and SD-4 have better dissolution characteristics when compared with 
SD-1 and SD-2. So the Rosuvastatin calcium-Starch phosphate solid dispersion was taken in the 
ratios of 1:3 and 1:4 for compression into tablets for immediate release of Rosuvastatin calcium. 
Formulations SD-3 and SD-4 was found to be optimum for formulating tablets in order to enhance 
its solubility.  
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FOR IR FORMULATION:  
PRECOMPRESSION STUDY: 
The drug and the formulated blends are evaluated for Precompression parameters. The results 
are given in the table 23. 
Table 23: Precompression study of drug and the formulated blends. 
Drug 
formulation  
Bulk density* 
  g/cm
3
 
Tapped 
density* 
g/cm
3
 
Compressibility 
index*(%) 
Hausner’s 
ratio*  
Angle of 
repose*  
(degree) 
RC 0.401 ±0.003 0.566± 0.034 34.90±0.4563 1.542±0.0045 42.909±0.3246 
RC-1 0.384 ±0.008 0.588 ±0.011 34.69 ±0.4073 1.531 
±0.0038 
41.030 ±0.1120 
RC-2 0.375 ±0.0042  0.598 ±0.013 35.02 ±0.3425 1.456 
±0.0034 
42.340 ±0.4025 
RC-3 0.421 ±0.0003 0.573 ±0.017 34.21 ±0.4563 1.512 
±0.0023 
41.393 ±0.4630 
 
The bulk density of IR Blends ranged from 0.384- 0.421 g/cm
3
 and tapped density ranged 
from 0.573- 0.598 g/cm
3
. The compressibility index of the IR granules ranged from 34.21-35.02% 
and Hausner’s ratio ranged from 1.456-1.531. The angle of repose of IR granules ranged from 41.03- 
41.39. The formulated blends show poor flow property. So wet granulation technique is used for 
preparing IR granules Rosuvastatin calcium. 
The IR granules were evaluated for bulk density, tapped density, compressibility index, 
Hausner’s ratio and angle of repose. The results are given in the table 24.  
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Table 24: Precompression study of immediate release granules. 
Drug 
formulatio
n  
Bulk density* 
  g/cm
3
 
Tapped 
density* 
g/cm
3
 
Compressibility 
index*(%) 
Hausner’s 
ratio*  
Angle of repose*  
(degree) 
RC-1 0.354 ±0.0018 0.558 ±0.041 16.69 ±0.3073 1.151 ±0.0018 32.030 ±0.2120 
RC-2 0.345 ±0.0032  0.588 ±0.023 15.02 ±0.2425 1.136 ±0.0024 31.340 ±0.3025 
RC-3 0.371 ±0.0023 0.553 ±0.007 15.21 ±0.3563 1.101 ±0.0013 30.393 ±0.5630 
 
The bulk density of IR Blends ranged from 0.345- 0.371 g/cm
3
 and tapped density ranged 
from 0.553- 0.588 g/cm
3
. The compressibility index of the IR granules ranged from 31.02-33.69% 
and Hausner’s ratio ranged from 1.136-1.151. The angle of repose of IR granules ranged from 
30.393- 32.030. The formulated IR granules show good flow property. 
Formulation development:  
Preparation of IR tablets of rosuvastatin calcium: 
Immediate release solid dispersion compressed layer of rosuvastatin calcium was prepared by 
wet granulation method. 
The formulations of immediate release solid dispersion layer of Rosuvastatin calcium (RC-1, RC-2 
and RC-3) were prepared using the super disintegrant sodium starch glycolate. 
The formulation were compressed on a 10 station tablet compression machine using 10/32 
concave punches.   
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POST COMPRESSION STUDY 
UNIFORMITY OF WEIGHT
58
: 
The uniformity of weight of the formulated tablets is given in the table 25. 
Table 25: Uniformity of weight of the formulated tablets. 
Formulation Uniformity of 
weight(mg)* 
RC-1 150.55±0.2315 
RC-2 152.55±0.3232 
RC-3 150.60±0.2211 
*MEAN±S.D (n=20) 
The tablets comply with the test for uniformity of weight. 
TABLET THICKNESS AND DIAMETER
71
: 
The thickness and diameter of the formulated tablets is given in the table 26 
Table 26: Thickness and Diameter of the formulated tablets. 
Formulation  Thickness 
(mm)* 
Diameter(mm)* 
RC-1 2.500±0.0038 8.000±0.0031 
RC-2 2.500±0.0087 8.000±0.0045 
RC-3 2.500±0.0024 8.000±0.0076 
*MEAN±S.D (n=10) 
The tablets have uniform thickness and diameter. 
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HARDNESS
71
: 
The hardness of the formulated tablets is given in the table 27 
Table 27: Hardness of the formulated tablets 
Formulation  Hardness 
Kg/cm
2
* 
RC-1 4.15±0.264 
RC-2 4.10±0.255 
RC-3 3.75±0.238 
*MEAN±S.D (n=10) 
All the formulated tablets showed sufficient mechanical strength to resist the 
transportation. 
FRIABILITY
71
: 
The Friability of the formulated tablets is given in the table 28 
Table 28: Friability of the formulated tablets 
Formulation  Friability * 
RC-1 0.320±0.0062 
RC-2 0.289±0.0102 
RC-3 0.295±0.0053 
*MEAN±S.D (n=20) 
The percentage friability of all the formulation was within acceptable limits
71
. 
DRUG CONTENT
48
: 
The Drug content of the formulated IR tablets is given in the table 29 and Fig 26 
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Table 29: Drug content of the formulated IR tablets 
Formulation  % Drug content * 
RC-1 98.95±0.0042 
RC-2 98.94±0.0052 
RC-3 97.33±0.0063 
*MEAN±S.D (n=6) 
Fig 26: Drug content of the formulated IR tablets 
 
The drug content of the IR tablets was within Pharmacopoeial limits
58
. 
DISINTEGRATION TIME
58
: 
The disintegration time of the IR tablets is given in the table 30 and Fig 27. 
Table 30: Disintegration time of the IR tablets 
 
*MEAN±S.D (n=6) 
 
96
97
98
99
RC-1 RC-2 RC-3
drug content 
drug content
Formulation  Disintegration 
time(minutes) * 
RC-1 2.35±0.0142 
RC-2 1.94±0.0072 
RC-3 1.33±0.0033 
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Fig 27: Disintegration time of the IR tablets  
 
 
The disintegration time of the IR tablets ranged from 1.33 to 2.35 minutes. The disintegration 
time of IR tablets containing solid dispersion of Rosuvastatin calcium-Starch phosphate in the ratio 
of 1:4 was found to be optimum for immediate disintegration of IR tablets. 
INVITRO DISSOLUTION STUDY
40
: 
The invitro dissolution of immediate release formulations of Rosuvastatin calcium is given in 
the Table 31 and Fig 28 
Table 31: invitro dissolution of immediate release formulation of Rosuvastatin calcium 
 
Time in 
Minutes 
Cumulative % drug release* 
RC-1 RC-2 RC-3 
5 19.525 35.370 52.081 
10 39.057 70.740 68.120 
15 46.057 77.790 101.292 
20 53.058 81.189  
30 73.060 98.209  
40 91.760 102.190  
50 99.890   
60 100.908   
*MEAN±S.D (n=6) 
0
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1
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2
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Fig 28: invitro dissolution of immediate release formulation of Rosuvastatin calcium 
 
The invitro dissolution of IR tablets showed that solid dispersion enhanced the dissolution of 
rosuvastatin calcium when compared to the conventional tablet RC-1. The solid dispersion tablet 
(RC-3) released the drug faster when compared to RC-2. Therefore formulation RC-3 was found 
optimum and selected for bilayer floating tablets.   
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FOR BILAYER FLOATING TABLETS: 
PRECOMPRESSION STUDY: 
The drug and the formulated blends of SR were evaluated for Precompression parameters. The 
results are given in the table 31. 
Table 32: Precompression study of drug and formulated blends
71 
Drug 
formulation 
Bulk 
density* 
g/cm
3
 
Tapped 
density* 
g/cm
3
 
Compressibility 
index*(%) 
Hausner’s 
ratio* 
Angle of 
repose* 
(degree) 
PH 0.500 ±0.0008 0.769 ±0.031 34.69 ±0.3073 1.538±0.0018 40.220±0.2143 
SR-1 0.367 ±0.0032 0.581 ±0.043 34.04 ±0.3016 1.181±0.0067 34.080 ±0.4120 
SR-2 0.323 ±0.0042  0.542 ±0.018 31.02 ±0.5425 1.136 ±0.0034 34.340 ±0.5025 
SR-3 0.341 ±0.0031 0.510 ±0.007 32.21 ±0.4563 1.121 ±0.0043 32.393 ±0.3630 
SR-4 0.340±0.0028 0.505±0.002 32.10±0.4102 1.164±0.0032 32.768±0.3426 
SR-5 0.356±0.0067 0.549±0.024 33.34±0.4201 1.149±0.0045 34.909±0.5625 
SR-6 0.342±0.0059 0.532±0.016 32.21±0.3520 1.120±0.0019 32.192±0.3542 
SR-7 0.321±0.0043 0.514±0.025 31.25±0.3211 1.140±0.0024 32.324±0.2110 
*MEAN±S.D (n=6) 
The bulk density of SR granules ranged from 0.321- 0.367 g/cm
3
 and tapped density ranged 
from 0.505- 0.581 g/cm
3
. The compressibility index of the SR granules ranged from 31.02-34.64 and 
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Hausner’s ratio ranged from 1.121-1.191. The angle of repose of SR granules ranged from 32.192- 
34.909. The formulated SR granules show good flow property. 
FORMULATION DEVELOPMENT 
PREPARATION OF REGIO-SELECTIVE BILAYER FLOATING TABLETS 
 Preparation of rosuvastatin starch phosphate solid dispersion  
 Optimized immediate release layer of rosuvastatin solid dispersion was prepared by wet 
granulation  
 Regio-selective sustained release layer of propranolol hydrochloride was prepared by wet 
granulation method 
Bilayer floating tablets of propranolol hydrochloride and rosuvastatin calcium solid 
dispersion was prepared by compressing the optimized formula of IR solid dispersion granules with 
various formulations of SR granules on a 10 station tablet compression machine using 12/32 concave 
punches 
POST COMPRESSION STUDIES OF BILAYER FLOATING TABLETS: 
UNIFORMITY OF WEIGHT
58
: 
The uniformity of weight of the formulated tablets is given in table 33. 
Table 33: Uniformity of weight of the formulated tablets. 
Formulation Uniformity of 
weight(mg)* 
RBFT-1 400.25±0.1215 
RBFT-2 400.15±0.1232 
RBFT-3 400.60±0.1111 
RBFT-4 400.65±0.1115 
RBFT-5 400.85±0.1012 
RBFT-6 400.20±0.1121 
RBFT-7 400.30±0.1201 
*MEAN±S.D (n=20) 
The tablets comply with the test for uniformity of weight. 
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TABLET THICKNESS AND DIAMETER
71
: 
The thickness and diameter of the formulated tablets is given in table 34. 
Table 34: thickness and diameter of the formulated tablets. 
Formulation  Thickness (mm)* Diameter(mm)* 
RBFT-1 3.950±0.0084 9.500±0.0327 
RBFT-2 3.945±0.0032 9.510±0.0119 
RBFT-3 3.854±0.0056 9.530±0.0312 
RBFT-4 4.007±0.0089 9.550±0.0167 
RBFT-5 3.960±0.0023 9.510±0.0253 
RBFT-6 3.890±0.0052 9.537±0.0234 
RBFT-7 3.850±0.0043 9.510±0.0127 
*MEAN±S.D (n=10) 
The tablets have uniform thickness and diameter. 
HARDNESS
71
: 
The hardness of the formulated tablets is given in table 35. 
Table 35: Hardness of the formulated tablets 
Formulation  Hardness Kg/cm
2
* 
RBFT-1 5.15±0.264 
RBFT-2 5.10±0.155 
RBFT-3 5.75±0.238 
RBFT-4 5.64±0.164 
RBFT-5 5.21±0.255 
RBFT-6 5.90±0.138 
RBFT-7 5.29±0.264 
*MEAN±S.D (n=10) 
All the formulated tablets showed sufficient mechanical strength to resist the transportation. 
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FRIABILITY
71
: 
The Friability of the formulated tablets is given in the table 36 
Table 36: Friability of the formulated tablets 
Formulation  Friability * 
RBFT-1 0.220±0.0022 
RBFT-2 0.389±0.0122 
RBFT-3 0.295±0.0033 
RBFT-4 0.320±0.0042 
RBFT-5 0.389±0.0102 
RBFT-6 0.395±0.0033 
RBFT-7 0.345±0.0029 
*MEAN±S.D (n=20) 
The percentage friability of all the formulation was within Pharmacopoeial limits
58
. 
INVITRO FLOATING STUDIES: 
The invitro floating characteristics of the formulated bilayer floating tablets is given in table 
37 and Fig 37 
Table 37: Invitro floating characteristics of the formulated bilayer floating tablets 
FORMULATION  FLOATING LAG 
TIME(MINUTES)  
FLOATING 
DURATION(HOURS) 
RBFT-1 2.50±0.045 11.30±0.112 
RBFT-2 2.10±0.045 12.43±0.103 
RBFT-3 1.89±0.118 12.30±0.313 
RBFT-4 1.76±0.218 12.46±0.212 
RBFT-5 2.03±0.220 12.05±0.271 
RBFT-6 1.39±0.210 12.34±0.231 
RBFT-7 1.03±0.231 12.59±0.023 
*MEAN±S.D (n=6) 
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Fig 29: Invitro floating lag time of RBFT 
 
 
Fig 30: Invitro floating duration of RBFT 
 
 
 
 
 
 
 
 
The floating duration ranged from 11.39 to 12.59 hours and the floating lag time ranged from 
1.03 to 2.50 minutes. The matrix integrity of the prepared floating tablets is good during the floating 
study. The formulation RBFT-7 exhibits optimum floating behavior when compared with all the 
other formulation. 
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DRUG CONTENT OF BILAYER FLOATING TABLET BY SIMULTANEOUS 
ESTIMATION METHOD: 
The drug content of propranolol hydrochloride and rosuvastatin calcium of the formulated 
bilayer floating tablets is given in table 38 and Fig 31 and 32. 
Table 38: Drug content of Bilayer floating tablet 
Formulation  % DRUG CONTENT* 
Rosuvastatin calcium  Propranolol hydrochloride  
RBFT-1 99.25±0.045 102.25±0.245 
RBFT-2 101.05±0.290 103.05±0.190 
RBFT-3 99.93±0.101 103.00±0.118 
RBFT-4 99.46±0.192 99.46±0.241 
RBFT-5 97.89±0.073 97.89±0.189 
RBFT-6 99.45±0.112 100.52±0.100 
RBFT-7 104.30±0.036 101.53±0.021 
*MEAN±S.D (n=6) 
Fig 31: Drug content of rosuvastatin calcium in RBFT 
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Fig 32: drug content of Propranolol hydrochloride in RBFT 
 
 
 
 
 
 
 
The drug content of rosuvastatin calcium and propranolol hydrochloride in bilayer floating 
tablet was found to be within the Pharmacopoeial limits
58
. 
IN VITRO DISSOLUTION STUDY: 
The invitro dissolution of drugs in the bilayer floating tablets is given in table 39,40 and fig 33. 
Table 39: invitro dissolution of rosuvastatin calcium in RBFT 
 *MEAN±S.D (n=6) 
 
 
TIME 
(MINUTES) 
 
CUMULATIVE % ROSUVASTATIN CALCIUM RELEASE* 
RBFT-1 RBFT-2 RBFT-3 RBFT-4 RBFT-5 RBFT-6 RBFT-7 
5 52.79±0.003 52.97±0.323 52.97±0.093 52.34±0.003 52.43±0.210 52.46±0.211 52.08±0.042 
10 68.30±0.034 67.73±0.324 68.48±0.024 68.87±0.420 68.46±0.201 68.75±0.262 68.12±0.033 
15 101.43±0.032 101.91±0.740 101.78±0.051 101.90±0.210 101.23±0.043 101.34±0.082 101.29±0.134 
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Table 40: Invitro dissolution study of propranolol hydrochloride in RBFT 
 
 
 
 
 
 
TIME 
(Hours) 
CUMULATIVE % PROPRANOLOL HYDROCHLORIDE RELEASE* 
RBFT-1 RBFT-2 RBFT-3 RBFT-4 RBFT-5 RBFT-6 RBFT-7 
1 `16.07±0.034 12.98±0.052 11.32±0.21 14.64±0.022 16.02±0.046 14.43±0.045 09.22±0.076 
2 24.24±0.032 20.72±0.084 20.45±0.045 21.04±0.034 22.33±0.043 21.43±0.050 14.85±0.094 
3 31.08±0.052 28.19±0.121 23.76±0.023 23.00±0.012 31.36±0.013 28.41±0.090 23.47±0.023 
4 40.77±0.021 33.99±0.092 31.86±0.052 31.99±0.054 38.09±0.018 37.26±0.056 34.63±0.043 
5 48.23±0.023 39.59±0.012 41.61±0.053 36.78±0.089 46.66±0.017 43.57±0.043 46.90±0.026 
6 61.88±0.362 45.05±0.034 42.01±0.089 42.94±0098 53.93±0.034 49.73±0.021 57.51±0.056 
7 65.75±0.021 62.04±0.027 51.71±0.037 51.67±0.034 63.19±0.032 60.53±0.034 67.49±0.094 
8 81.52±0.024 78.75±0.054 55.05±0.054 55.88±0.032 71.69±0.052 68.82±0.021 73.91±0.043 
9 100.54±0.078 90.28±0.065 67.79±0.089 67.47±0.043 99.58±0.074 86.94±0.054 83.06±0.023 
10  99.00±0.075 84.53±0.056 86.66±0.024  98.82±0.067 89.97±0.045 
11  101.26±0.073 100.64±0.035 95.90±0.078     
104.77±0.057 
95.64±0.086 
12    104.03±0.033   100.01±0.014 
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Fig 33: Invitro dissolution study of propranolol hydrochloride in RBFT 
 
The results of invitro dissolution study of regio-selective bilayer floating tablets showed that 
the formulation RBFT-1, RBFT-2 and RBFT-3 containing HPMC K100 polymer released the entire 
drug within 9,10 and 11 hours respectively. The formulations RBFT-5, RBFT-6 and RBFT-7 
containing HPMC K4M polymer have sustained the drug release from the bilayer floating tablet for 
more hours (11,11 and 12 hours respectively). Though HPMC K100 were added in more amount in 
the formulations RBFT-1, RBFT-2, RBFT-3 and RBFT-4 the release of the drug from the tablet was 
not sustained for more hours when compared with formulations RBFT-5, RBFT-6 and RBFT-7 in 
which HPMC K4M were present. All the formulations contain ethyl cellulose, xanthan gum in 
similar quantities. The only variable adjusted was the HPMC K4M and HPMC K100. In case of 
RBFT-4 the polymer HPMCK100 was sustained the drug release over period of 12 hours in higher 
concentrations then that of all other formulations. It was concluded that the formulation RBFT-7 
containing HPMC K4M in 20% was found to be the best formulation to sustain the release of the 
drug over the period of 12 hours.  Other formulation released the drug before 12 hours. Therefore 
RBFT-7 can be the best formulation.    
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SWELLING STUDIES:  
Swelling study was carried out on the optimized bilayer floating tablets. The % swelling of 
the tablets is given in the table 41 and fig 34 
Table 41: swelling index of optimized formulation 
Time in hours % swelling* 
0 0 
1 40.32 
2 83.26 
4 130.14 
6 165.67 
8 209.42 
10 246.20 
12 259.19 
 
Fig 34: swelling index of optimized formulation 
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The swelling index of the bilayer floating tablets showed that the floating matrix layer 
maintained their integrity and increased swelling during the study. The study showed that the 
combination of HPMC K4M and Xanthan gum polymers has higher swelling index. More swelling 
resulted in more retarded release of the drug from the matrix layer 
 INVITRO RELEASE KINETICS: 
The values obtained from invitro dissolution of Propranolol hydrochloride from bilayer 
floating tablet were fitted in various kinetic models. The results are given in table 42 and Figure 
34,35,36,37 and 38. 
Table 42: Invitro Release Kinetics of BFT 
Time in 
Hours 
% Cum. 
Drug 
release 
% Cum. 
Drug 
remaining 
Log% 
Cum. 
drug 
remaining 
Square 
root of 
time 
Log time Log% 
cum. 
Drug 
release 
Cube root 
of % drug 
remaining 
0 0 100 2.00000 0  ∞  ∞ 4.641588 
1 9.226 90.774 1.95796 1.00000 0 0.965013 4.494214 
2 14.859 85.141 1.93013 1.41421 0.30102 1.171989 4.399259 
3 23.471 76.529 1.88382 1.73205 0.47712 1.370531 4.245628 
4 34.631 65.369 1.81537 2.00000 0.60205 1.539465 4.028319 
5 46.906 53.094 1.72504 2.23606 0.69897 1.671228 3.758505 
6 57.516 42.484 1.62822 2.44940 0.77815 1.759788 3.489328 
7 67.490 32.510 1.51201 2.64575 0.84509 1.829239 3.191579 
8 73.916 26.084 1.41637 2.82840 0.90308 1.868738 2.965683 
9 83.064 16.936 1.22881 3.00000 0.95424 1.919412 2.568050 
10 89.978 10.022 1.00095 3.16224 1.00000 1.954136 2.156013 
11 95.647 4.353 0.63878 3.31662 1.04139 1.980671 1.632787 
12 99.195 0.0150 0.09420 3.46413 1.07918 1.996489 0.246621 
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Fig 34: Zero order release kinetics 
 
 
 
 
 
 
 
 
 
Fig 35: First order release kinetics 
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Fig 36: Higuchi Diffusion kinetics 
 
 
 
 
 
 
 
 
 
 
Fig 37: Korsmeyer Peppas Equation 
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Fig 38: Hixon Crowell cube root equation 
 
 
Determination of drug release mechanism of optimized bilayer floating tablets: 
 The order of release of drug was found to be zero order, in which R2 value was close to 1. 
 The n value of Korsmeyer Peppas equation   was found to be 1.0302. It was concluded that 
the release followed non- Fickian transport. 
 Good correlation coefficients are obtained for Hixon Crowell cube root and Higuchi 
equation. Propranolol hydrochloride is a hydrophilic drug with a hydrophilic matrix 
 Swelling and hydration of the polymer matrix, Dissolution of the drug in the polymer matrix 
and diffusion of the drug through the polymer plays role in the drug release. The results 
showed that the formulation followed zero order release  
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STABILITY STUDY: 
The optimized bilayer floating tablets were subjected to stability studies and the results are 
given in Table 43, 44. 
Table 44: stability study of physical parameters of optimized formulation  
PARAMETERS  INITIAL  1
ST
  MONTH  2
ND
 MONTH  3
RD
 MONTH  
Uniformity of 
weight *(mg) 
400.30±0.1278 400.60±0.1109 400.10±0.1022 400.20±0.1334 
Thickness**  (mm) 3.850±0.0043 3.870±0.0046 3.855±0.0093 3.850±0.0013 
Diameter **(mm) 9.510±0.0139 9.510±0.0190 9.510±0.0203 9.510±0.0237 
Hardness**(kg/cm2) 5.29±0.264 5.45±0.227 5.65±0.214 5.30±0.236 
Friability* (%) 
 
0.345±0.0029 0.365±0.0090 0.370±0.0019 0.338±0.0034 
Floating lag time*** 
(min) 
1.03±0.231 1.09±0.121 1.08±0.045 1.01±0.099 
Floating 
duration***(hours) 
12.59±0.023 12.18±0.120 12.72±0.228 12.24±0.083 
*Mean ±SD (n=20) ** Mean ±SD (n=10)*** Mean ±SD(n=6) 
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Table 44: Assay and Dissolution profile of bilayer floating tablets 
Time interval 
(month) 
% Drug content* Cumulative % release* 
Rosuvastatin 
calcium 
Propranolol 
hydrochloride 
Rosuvastatin 
calcium 
(for 15 mins) 
Propranolol 
hydrochloride 
(for 12 hours) 
1 month 104.30±0.036 101.53±0.021 101.29±0.014 100.01±0.148 
2 month 103.50±0.052 101.03±0.036 101.14±0.034 100.31±0.048 
3 month 103.79±0.043 101.01±0.024 101.29±0.014 100.20±0.014 
*Mean ±SD (n=3) 
No significant changes were observed in the physical appearance, colour and uniformity of 
weight, hardness, drug content, floating characteristics and drug release of bilayer floating tablets of 
the optimized batch at 40
0
C /75% RH. The bilayer floating tablets are stable. 
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SUMMARY AND CONCLUSION 
 The present study was aimed to develop regio-selective bilayer floating tablets 
containing propranolol hydrochloride as SR layer and Rosuvastatin calcium as IR 
layer for hypertensive patients. Combination therapy of beta-blocker and HMGCo-A 
Reductase inhibitors is recommended for treatment of hypertensive patients. 
 The drug excipient interaction was investigated with FTIR spectroscopy. The study 
indicated that there was no interaction between the drug and the excipients used in the 
formulations.  
 The floating matrix layer was formulated with hydrophobic polymer (ethyl cellulose) 
and hydrophilic polymers (HPMC K4M, HPMC K100 and Xanthan gum) to retard 
the drug release upto 12 hours.  
 The rosuvastatin calcium solid dispersion of different ratios (1:1, 1:2, 1:3, and 1:4) 
was prepared by taking starch phosphate as a novel carrier for the drug.   
 From the dissolution results of rosuvastatin solid dispersion, two ratios which exhibit 
enhanced dissolution of rosuvastatin calcium were selected.  
 The immediate release rosuvastatin calcium layer was formulated with sodium starch 
glycolate (4%). 
 All the formulations were evaluated for physical characteristics, drug content, 
dissolution, release kinetics and stability studies. 
 The tablets were formulated by wet granulation method because the flow property of 
the drugs and the blends were poor. 
 The formulated granules were evaluated and showed good flow property. 
 The tablets were found to be within the limits with respect to uniformity of weight, 
hardness, thickness, diameter and friability.  
 The disintegration time of the IR tablets containing solid dispersion in ratio of 1:4 and 
SSG 4 % was found to be optimum. 
 The drug content of the formulated IR tablets was found to be within the limits. 
 The invitro dissolution studies were performed for all the IR-SD formulations. The 
formulations RC-1, RC-2 and RC-3 released 46.05, 77.79 and 101.29 at the end of 15 
minutes. Thus the formulation RC-3 has enhanced solubility of rosuvastatin calcium 
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and it was optimized formulation and selected for compression with bilayer floating 
tablets.  
 The drug content of the formulated Propranolol hydrochloride SR floating tablets was 
found to be within Pharmacopoeial limits. 
 The drug content of the bilayer floating tablets was estimated by simultaneous 
estimation method and it was found to be within Pharmacopoeial limits. 
 In vitro dissolution studies were performed for all the bilayer floating tablet 
formulations. The formulation RBFT-7 containing HPMC K4M 20% Released the 
drug upto 12 hours. 
 Floating lag time of bilayer floating tablets was within 3 minutes and floating 
duration was more than 12 hours. 
 In vitro dissolution study was performed for bilayer floating tablets. At the end of 15 
minutes the release was found to be 101.29% for immediate release layer of 
Rosuvastatin calcium and at the end of 12
th
 hour the release was found to be 101.01 
% for sustained release layer of Propranolol hydrochloride. 
 Release kinetics of sustained release layer of bilayer floating tablets followed zero 
order release kinetics. The release of the drug was dependent on diffusion, swelling 
and erosion of the polymer. 
 The stability studies showed that the formulated bilayer floating tablets were stable 
and did not show any significant changes in the physical characteristics, drug content 
and dissolution. The results obtained were found to be within acceptable limits. Thus 
the formulated bilayer floating tablets of propranolol hydrochloride and rosuvastatin 
calcium was found to be stable. 
 Regio- selective bilayer floating tablets of rosuvastatin calcium for immediate release 
and propranolol hydrochloride for sustained release was formulated to reduce the 
frequency of administration and to reduce hypertension     
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FUTURE SCOPE 
This work can be extended for 
 Permeability improvement of rosuvastatin calcium.   
 Invivo studies and invitro- invivo correlation of regio-selective bilayer 
floating tablets. 
 Clinical studies in healthy volunteers and other biopharmaceutical studies. 
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